

Quarterly Information - ITR

Diagnósticos da América S.A.

September 30, 2014

Contents

Company Data

| | |
|---------------------------------|---|
| Capital Stock Composition | 1 |
| Cash Earnings..... | 2 |

INDIVIDUAL QUARTERLY FINANCIAL INFORMATION

| | |
|--|---|
| Statement of Financial Position - Assets..... | 3 |
| Statement of Financial Position - Liabilities..... | 4 |
| Statement of Income..... | 5 |
| Statement of Comprehensive Income | 6 |
| Statement of Cash Flows | 7 |

Statement of Changes in Equity

| | |
|-------------------------------|----|
| 1/1/2014 to 9/30/2014..... | 8 |
| 1/1/2013 to 9/30/2013..... | 9 |
| Statement of Value Added..... | 10 |

CONSOLIDATED QUARTERLY FINANCIAL INFORMATION

| | |
|--|----|
| Statement of Financial Position - Assets..... | 11 |
| Statement of Financial Position - Liabilities..... | 12 |
| Statement of Income..... | 13 |
| Statement of Comprehensive Income | 14 |
| Statement of Cash Flows | 15 |

Statement of Changes in Equity

| | |
|--|----|
| 1/1/2014 to 9/30/2014..... | 16 |
| 1/1/2013 to 9/30/2013..... | 17 |
| Statement of Value Added..... | 18 |
| Comments on the Company's Performance | 19 |
| Notes to Quarterly Financial Information..... | 25 |
| Other Information Considered Relevant by the Company | 71 |

Reports and Representations

| | |
|--|----|
| Independent Auditor's Review Report on Quarterly Financial Information..... | 72 |
| Opinions and Statements/Statement of Officers on the Quarterly Financial Information | 74 |
| Opinions and Declarations/Statement of Officers on the Independent Auditors Review Report..... | 75 |

Company data / Capital Composition

| Number of shares (Units) | Current quarter 9/30/2014 |
|-------------------------------------|--------------------------------------|
| Paid-in capital | |
| Common shares | 311,803,015 |
| Preferred shares | - |
| Total | 311,803,015 |
| Treasury shares | |
| Common shares | 1,052,459 |
| Preferred shares | - |
| Total | 1,052,459 |

Company Data / Cash Earnings

| Event | Approval | Earnings | Initial Payment | Share | Class of Share | Earnings per share (Reais / Share) |
|------------------------|-----------------|-----------------|------------------------|--------------|-----------------------|---|
| Annual General Meeting | 4/28/2014 | Dividends | 6/16/2014 | Common | | 0.10100 |

Individual Quarterly Financial Information / Statement of Financial Position - Assets

(R\$ in thousands)

| Code | Description | Current Quarter 9/30/2014 | Previous Year 12/31/2013 |
|---------------|-------------------------------------|------------------------------|-----------------------------|
| 1 | Total assets | 4,602,722 | 4,480,344 |
| 1.01 | Current assets | 1,294,225 | 1,055,844 |
| 1.01.01 | Cash and cash equivalents | 481,021 | 486,571 |
| 1.01.03 | Accounts receivable | 587,690 | 389,860 |
| 1.01.03.01 | Trade accounts receivable | 587,690 | 389,860 |
| 1.01.04 | Inventories | 59,457 | 40,406 |
| 1.01.06 | Taxes recoverable | 136,370 | 107,299 |
| 1.01.06.01 | Current taxes recoverable | 136,370 | 107,299 |
| 1.01.07 | Prepaid expenses | 2,256 | 883 |
| 1.01.08 | Other current assets | 27,431 | 30,825 |
| 1.01.08.03 | Other | 27,431 | 30,825 |
| 1.01.08.03.01 | Derivative financial instruments | - | 85 |
| 1.01.08.03.20 | Other receivables | 27,431 | 30,740 |
| 1.02 | Non-current assets | 3,308,497 | 3,424,500 |
| 1.02.01 | Long-term receivables | 93,797 | 143,012 |
| 1.02.01.01 | Marketable securities at fair value | 26,954 | 26,184 |
| 1.02.01.01.01 | Marketable securities | 26,954 | 26,184 |
| 1.02.01.03 | Accounts receivable | 512 | 295 |
| 1.02.01.03.01 | Trade accounts receivable | 512 | 295 |
| 1.02.01.07 | Prepaid expenses | 945 | 788 |
| 1.02.01.08 | Receivables from related parties | 16,539 | 25,000 |
| 1.02.01.08.02 | Receivables from subsidiaries | 16,539 | 25,000 |
| 1.02.01.09 | Other non-current assets | 48,847 | 90,745 |
| 1.02.01.09.03 | Derivative financial instruments | - | 22 |
| 1.02.01.09.04 | Judicial deposits | 48,641 | 90,695 |
| 1.02.01.09.05 | Other non-current assets | 206 | 28 |
| 1.02.02 | Investments | 270,856 | 453,127 |
| 1.02.02.01 | Equity interest | 270,177 | 452,503 |
| 1.02.02.01.02 | Investments in subsidiaries | 270,177 | 452,503 |
| 1.02.02.02 | Investment properties | 679 | 624 |
| 1.02.02.02.20 | Others | 679 | 624 |
| 1.02.03 | Property and equipment | 639,324 | 543,082 |
| 1.02.04 | Intangible assets | 2,304,520 | 2,285,279 |
| 1.02.04.01 | Intangible assets | 2,304,520 | 2,285,279 |

Individual Quarterly Financial Information / Statement of Financial Position - Liabilities

(R\$ in thousands)

| Code | Description | Current Quarter 9/30/2014 | Previous Year 12/31/2013 |
|---------------|--|------------------------------|-----------------------------|
| 2 | Total liabilities | 4,602,722 | 4,480,344 |
| 2.01 | Current liabilities | 723,920 | 565,634 |
| 2.01.01 | Social security and labor liabilities | 139,578 | 81,270 |
| 2.01.02 | Trade accounts payable | 79,226 | 45,804 |
| 2.01.03 | Tax liabilities | 26,174 | 10,476 |
| 2.01.04 | Loans and financing | 389,593 | 326,540 |
| 2.01.04.01 | Loans and financing | 37,890 | 6,628 |
| 2.01.04.02 | Debentures | 351,703 | 319,912 |
| 2.01.05 | Other liabilities | 89,349 | 101,544 |
| 2.01.05.02 | Other | 89,349 | 101,544 |
| 2.01.05.02.01 | Dividends and interest on equity payable | 8 | 31,188 |
| 2.01.05.02.04 | Taxes in installments | 1,354 | 1,108 |
| 2.01.05.02.05 | Accounts payable for acquisition of subsidiaries | 1,758 | 1,689 |
| 2.01.05.02.06 | Uncovered liability of subsidiaries | 4,341 | - |
| 2.01.05.02.08 | Other payables | 81,888 | 67,559 |
| 2.02 | Non-current liabilities | 1,066,452 | 1,206,496 |
| 2.02.01 | Loans and financing | 857,719 | 1,038,617 |
| 2.02.01.01 | Loans and financing | 52,677 | 1,803 |
| 2.02.01.02 | Debentures | 805,042 | 1,036,814 |
| 2.02.02 | Other liabilities | 48,333 | 48,174 |
| 2.02.02.02 | Other | 48,333 | 48,174 |
| 2.02.02.02.03 | Taxes in installments | 11,673 | 9,430 |
| 2.02.02.02.04 | Accounts payable for acquisition of subsidiaries | 33,595 | 35,061 |
| 2.02.02.02.06 | Other payables | 3,065 | 3,683 |
| 2.02.03 | Deferred taxes | 101,356 | 82,211 |
| 2.02.03.01 | Deferred income and social contribution taxes | 101,356 | 82,211 |
| 2.02.04 | Provisions | 59,044 | 37,494 |
| 2.02.04.01 | Provisions for tax, civil and labor risks | 59,044 | 37,494 |
| 2.03 | Equity | 2,812,350 | 2,708,214 |
| 2.03.01 | Paid-in capital | 2,234,135 | 2,234,135 |
| 2.03.02 | Capital reserves | 50,217 | 49,727 |
| 2.03.02.02 | Special reserve for goodwill on merger | 65,366 | 65,427 |
| 2.03.02.04 | Granted options | 1,756 | 2,917 |
| 2.03.02.05 | Treasury shares | (16,905) | (18,617) |
| 2.03.04 | Revenue reserves | 423,532 | 423,409 |
| 2.03.04.01 | Legal reserve | 30,128 | 30,128 |
| 2.03.04.05 | Retained profit reserve | 393,404 | 393,090 |
| 2.03.04.08 | Additional proposed dividend | - | 191 |
| 2.03.05 | Accumulated profits and losses | 103,837 | - |
| 2.03.06 | Other comprehensive income | 629 | 943 |

Individual Quarterly Financial Information / Statement of Income

(R\$ in thousands)

| Code | Description | Current quarter | Accumulated | Current quarter | Accumulated |
|------------|---|--------------------------|--|--------------------------|---|
| | | 7/1/2014 to 9/30/2014 | current period 1/1/2014 to 9/30/2014 | 7/1/2013 to 9/30/2013 | previous period 1/1/2013 to 9/30/2013 |
| 3.01 | Revenue from products sold and/or services rendered | 663,890 | 1,625,521 | 461,179 | 1,330,874 |
| 3.02 | Cost of products sold and/or services rendered | (436,979) | (1,112,884) | (312,440) | (916,410) |
| 3.03 | Gross Profit | 226,911 | 512,637 | 148,739 | 414,464 |
| 3.04 | Operating income/expenses | (136,034) | (302,858) | (78,035) | (238,871) |
| 3.04.02 | General and administrative expenses | (140,113) | (364,280) | (101,086) | (290,313) |
| 3.04.04 | Other operating income | 151 | 557 | 8,182 | 8,112 |
| 3.04.06 | Equity pickup | 3,928 | 60,865 | 14,869 | 43,330 |
| 3.05 | Income before financial income/expenses and taxes | 90,877 | 209,779 | 70,704 | 175,593 |
| 3.06 | Financial income/expenses | (26,284) | (78,089) | (20,927) | (50,562) |
| 3.06.01 | Financial income | 22,528 | 51,556 | 36,887 | 66,083 |
| 3.06.02 | Financial expenses | (48,812) | (129,645) | (57,814) | (116,645) |
| 3.07 | Income before income and social contribution taxes | 64,593 | 131,690 | 49,777 | 125,031 |
| 3.08 | Income and social contribution taxes | (21,086) | (27,853) | (13,867) | (30,440) |
| 3.08.01 | Current | (6,610) | (6,610) | - | - |
| 3.08.02 | Deferred | (14,476) | (21,243) | (13,867) | (30,440) |
| 3.09 | Net income from continuing operations | 43,507 | 103,837 | 35,910 | 94,591 |
| 3.11 | Net income for the period | 43,507 | 103,837 | 35,910 | 94,591 |
| 3.99 | Earnings per share (reais/share) | | | | |
| 3.99.01 | Basic earnings per share | | | | |
| 3.99.01.01 | Common shares | 0.14001 | 0.33415 | 0.11560 | 0.30450 |
| 3.99.02 | Diluted earnings per share | | | | |
| 3.99.02.01 | Common shares | 0.13992 | 0.33394 | 0.11548 | 0.30419 |

Individual Quarterly Financial Information / Statement of Comprehensive Income

(R\$ in thousands)

| Code | Description | Current quarter 7/1/2014 to 9/30/2014 | Accumulated current year 1/1/2014 to 9/30/2014 | Previous quarter 7/1/2013 to 9/30/2013 | Accumulated previous year 1/1/2013 to 9/30/2013 |
|-------------|-------------------------------------|--|---|---|--|
| 4.01 | Net income for the period | 43,507 | 103,837 | 35,910 | 94,591 |
| 4.03 | Comprehensive income for the period | 43,507 | 103,837 | 35,910 | 94,591 |

Individual Quarterly Financial Information / Statement of Cash Flows**(R\$ in thousands)**

| Code | Description | Accumulated current period 1/1/2014 to 9/30/2014 | Accumulated previous period 1/1/2013 to 9/30/2013 |
|-------------|---|---|--|
| 6.01 | Net cash from operating activities | 315,803 | 144,046 |
| 6.01.01 | Cash from operations | 323,599 | 223,783 |
| 6.01.01.01 | Net income for the period | 103,837 | 94,591 |
| 6.01.01.02 | Depreciation and amortization | 110,259 | 95,236 |
| 6.01.01.03 | Restatement of contingencies | 27,531 | 12,498 |
| 6.01.01.04 | Deferred taxes | 21,243 | 30,440 |
| 6.01.01.05 | Restatement of interest and exchange variation on loans | 109,823 | 64,067 |
| 6.01.01.06 | Gain on sale of property and equipment | 1,380 | 3,105 |
| 6.01.01.07 | Stock-option plan | 491 | 667 |
| 6.01.01.08 | Equity pickup | (60,865) | (43,330) |
| 6.01.01.09 | Gain on interest in subsidiaries | 480 | 279 |
| 6.01.01.10 | Provision for disallowance and default | 9,420 | (33,770) |
| 6.01.02 | Changes in assets and liabilities | (7,796) | (79,737) |
| 6.01.02.01 | Increase in trade accounts receivable and other receivables | (51,985) | (21,619) |
| 6.01.02.02 | (Increase) Decrease in inventories | (679) | 272 |
| 6.01.02.03 | Decrease in other current assets | 5,428 | (11,031) |
| 6.01.02.04 | Decrease (increase) in other non-current assets | 29,573 | 8,166 |
| 6.01.02.05 | Increase in trade accounts payable | 15,834 | (1,925) |
| 6.01.02.06 | Increase (Decrease) in accounts payable and provisions | (5,967) | (53,600) |
| 6.02 | Net cash used in investing activities | 29,277 | (60,692) |
| 6.02.01 | Additions to property and equipment | (85,874) | (68,446) |
| 6.02.02 | Additions to intangible assets | (16,232) | (23,251) |
| 6.02.06 | Investments in subsidiaries | - | (22,485) |
| 6.02.08 | Interest on equity received | 12,513 | 47,439 |
| 6.02.09 | Proceeds from sale of property and equipment | 92 | 6,051 |
| 6.02.10 | Increase of Cash and cash equivalents - Intercompany | 77,788 | - |
| 6.02.11 | Capital Increase - Intercompany | (43,010) | - |
| 6.02.12 | Capital Decrease - Intercompany | 84,000 | - |
| 6.03 | Net cash (used in) from financing activities | 350,630 | (73,399) |
| 6.03.01 | Loans received | 3,405 | - |
| 6.03.02 | Payment of loans | 246,822 | (13,233) |
| 6.03.07 | Dividends and interest on equity reserve paid | (31,371) | (20,500) |
| 6.03.08 | Interest paid | (75,842) | (39,666) |
| 6.05 | (Decrease) increase in cash and cash equivalents | (5,550) | 9,955 |
| 6.05.01 | At beginning of period | 486,571 | 152,546 |
| 6.05.02 | At end of period | 481,021 | 162,501 |

Individual Quarterly Financial Information / Statement of Changes in Equity - 1/1/2014 to 9/30/2014**(R\$ in thousands)**

| Code | Description | Paid-in Capital | Capital Reserve, Granted options and treasury shares | Income reserve | Retained earnings | Other comprehensive income | Equity |
|-------------|--------------------------------|------------------------|---|---------------------------|------------------------------|---|---------------|
| 5.01 | Opening balances | 2,234,135 | 49,727 | 423,409 | - | 943 | 2,708,214 |
| 5.03 | Adjusted opening balances | 2,234,135 | 49,727 | 423,409 | - | 943 | 2,708,214 |
| 5.04 | Transactions with shareholders | - | 490 | - | - | - | 490 |
| 5.04.03 | Granted options | - | 490 | - | - | - | 490 |
| 5.05 | Total comprehensive income | - | - | - | 103,837 | - | 103,837 |
| 5.05.01 | Net income of the period | - | - | - | 103,837 | - | 103,837 |
| 5.06 | Internal changes in equity | - | - | 123 | - | -314 | -191 |
| 5.06.04 | Depreciation of deemed cost | - | - | -191 | - | - | -191 |
| 5.06.05 | Additional dividends paid | - | - | 314 | - | -314 | - |
| 5.07 | Closing balances | 2,234,135 | 50,217 | 423,532 | 103,837 | 629 | 2,812,350 |

Individual Quarterly Financial Information / Statement of Changes in Equity - 1/1/2013 to 9/30/2013**(R\$ in thousands)**

| Code | Description | Paid-in Capital | Capital Reserve, Granted options and treasury shares | Income reserve | Retained earnings | Other comprehensive income | Equity |
|-------------|--------------------------------|------------------------|---|---------------------------|------------------------------|---|---------------|
| 5.01 | Opening balances | 2,234,135 | 48,171 | 322,933 | - | 1,571 | 2,606,810 |
| 5.03 | Adjusted opening balances | 2,234,135 | 48,171 | 322,933 | - | 1,571 | 2,606,810 |
| 5.04 | Transactions with shareholders | - | 666 | - | - | - | 666 |
| 5.04.03 | Granted options | - | 666 | - | - | - | 666 |
| 5.05 | Total comprehensive income | - | - | - | 94,591 | - | 94,591 |
| 5.05.01 | Net income for the period | - | - | - | 94,591 | - | 94,591 |
| 5.06 | Internal changes in equity | - | - | 202 | - | -471 | -269 |
| 5.06.04 | Depreciation of deemed cost | - | - | 471 | - | -471 | - |
| 5.06.05 | Additional dividends paid | - | - | -269 | - | - | -269 |
| 5.07 | Closing balances | 2,234,135 | 48,837 | 323,135 | 94,591 | 1,100 | 2,701,798 |

Individual Quarterly Financial Information / Statement of Value Added**(R\$ in thousands)**

| Code | Description | Accumulated current period 1/1/2014 to 9/30/2014 | Accumulated previous period 1/1/2013 to 9/30/2013 |
|-------------|---|---|--|
| 7.01 | Revenue | 1,783,390 | 1,479,707 |
| 7.01.01 | Sales of goods, products and services | 1,782,945 | 1,471,693 |
| 7.01.02 | Other revenue | 557 | 8,112 |
| 7.01.04 | (Reversal of) allowance for doubtful accounts | (112) | (98) |
| 7.02 | Inputs acquired from third parties | (855,448) | (695,624) |
| 7.02.01 | Cost of products, goods and services sold | (615,087) | (504,108) |
| 7.02.02 | Materials, energy, third-party services and other | (240,361) | (191,516) |
| 7.03 | Gross value added | 927,942 | 784,083 |
| 7.04 | Retentions | (110,259) | (95,236) |
| 7.04.01 | Depreciation, amortization and depletion | (110,259) | (95,236) |
| 7.05 | Net value added produced | 817,683 | 688,847 |
| 7.06 | Transferred value added received | 112,421 | 109,413 |
| 7.06.01 | Equity pickup | 60,865 | 43,330 |
| 7.06.02 | Financial income | 51,556 | 66,083 |
| 7.07 | Total value added to be distributed | 930,104 | 798,260 |
| 7.08 | Distribution of value added | 930,104 | 798,260 |
| 7.08.01 | Personnel | 399,240 | 332,708 |
| 7.08.02 | Taxes, fees and contributions | 210,188 | 178,210 |
| 7.08.03 | Debt remuneration | 216,839 | 192,751 |
| 7.08.04 | Equity remuneration | 103,837 | 94,591 |
| 7.08.04.03 | Retained profits | 103,837 | 94,591 |

Consolidated Quarterly Financial Information / Statement of Financial Position - Assets

(R\$ in thousands)

| Code | Description | Current Quarter 9/30/2014 | Previous Year 12/31/2013 |
|---------------|---|------------------------------|-----------------------------|
| 1 | Total assets | 4,737,194 | 4,691,811 |
| 1.01 | Current assets | 1,548,232 | 1,438,626 |
| 1.01.01 | Cash and cash equivalents | 516,605 | 535,881 |
| 1.01.02 | Marketable securities | 75,547 | 72,980 |
| 1.01.02.01 | Marketable securities at fair value | 75,547 | 72,980 |
| 1.01.02.01.01 | Securities for trading | 75,547 | 72,980 |
| 1.01.03 | Accounts receivable | 678,627 | 566,262 |
| 1.01.03.01 | Trade accounts receivable | 678,627 | 566,262 |
| 1.01.04 | Inventories | 65,185 | 59,383 |
| 1.01.06 | Taxes recoverable | 182,592 | 169,696 |
| 1.01.06.01 | Current taxes recoverable | 182,592 | 169,696 |
| 1.01.07 | Prepaid expenses | 2,351 | 897 |
| 1.01.08 | Other current assets | 27,325 | 33,527 |
| 1.01.08.03 | Other | 27,325 | 33,527 |
| 1.01.08.03.01 | Derivative financial instruments | - | 85 |
| 1.01.08.03.20 | Other receivables | - | 33,442 |
| 1.02 | Non-current assets | 3,188,962 | 3,253,185 |
| 1.02.01 | Long-term receivables | 148,824 | 200,517 |
| 1.02.01.01 | Marketable securities at fair value | 37,330 | 37,793 |
| 1.02.01.01.01 | Marketable Securities | 37,330 | 37,793 |
| 1.02.01.03 | Accounts receivable | 3,182 | 5,940 |
| 1.02.01.03.01 | Trade accounts receivable | 3,182 | 5,940 |
| 1.02.01.06 | Deferred taxes | 56,651 | 58,002 |
| 1.02.01.06.01 | Deferred income and social contribution taxes | 56,651 | 58,002 |
| 1.02.01.07 | Prepaid expenses | 945 | 789 |
| 1.02.01.09 | Other non-current assets | 50,716 | 97,993 |
| 1.02.01.09.03 | Derivative financial instruments | - | 22 |
| 1.02.01.09.04 | Judicial deposits | 50,506 | 95,540 |
| 1.02.01.09.05 | Other non-current assets | 210 | 2,431 |
| 1.02.02 | Investments | 799 | 786 |
| 1.02.02.02 | Investment Properties | 799 | 786 |
| 1.02.02.02.01 | Other | 799 | 786 |
| 1.02.03 | Property and equipment | 692,312 | 720,180 |
| 1.02.04 | Intangible assets | 2,347,027 | 2,331,702 |
| 1.02.04.01 | Intangible assets | 2,347,027 | 2,331,702 |

Consolidated Quarterly Financial Information / Statement of Financial Position - Liabilities and Equity

(R\$ in thousands)

| Code | Description | Current Quarter 9/30/2014 | Previous Year 12/31/2013 |
|---------------|--|------------------------------|-----------------------------|
| 2 | Total liabilities | 4,737,194 | 4,691,811 |
| 2.01 | Current liabilities | 834,802 | 730,778 |
| 2.01.01 | Social security and labor liabilities | 154,220 | 103,659 |
| 2.01.02 | Trade accounts payable | 87,530 | 65,479 |
| 2.01.03 | Tax liabilities | 33,814 | 22,386 |
| 2.01.04 | Loans and financing | 464,180 | 420,854 |
| 2.01.04.01 | Loans and financing | 112,477 | 100,942 |
| 2.01.04.02 | Debentures | 351,703 | 319,912 |
| 2.01.05 | Other liabilities | 95,058 | 118,400 |
| 2.01.05.02 | Other | 95,058 | 118,400 |
| 2.01.05.02.01 | Dividends and Interest equity payable | 78 | 31,255 |
| 2.01.05.02.04 | Taxes in installments | 1,861 | 4,293 |
| 2.01.05.02.05 | Accounts payable for acquisition of subsidiaries | 1,758 | 1,689 |
| 2.01.05.02.20 | Other accounts payable | 91,361 | 81,163 |
| 2.02 | Non-current liabilities | 1,089,176 | 1,252,223 |
| 2.02.01 | Loans and financing | 857,719 | 1,054,321 |
| 2.02.01.01 | Loans and financing | 52,677 | 17,507 |
| 2.02.01.02 | Debentures | 805,042 | 1,036,814 |
| 2.02.02 | Other liabilities | 68,880 | 75,246 |
| 2.02.02.02 | Other | 68,880 | 75,246 |
| 2.02.02.02.03 | Taxes in installments | 21,844 | 24,892 |
| 2.02.02.02.04 | Accounts payable for acquisition of subsidiaries | 43,971 | 46,670 |
| 2.02.02.02.20 | Other accounts payable | 3,065 | 3,684 |
| 2.02.03 | Deferred taxes | 101,356 | 82,211 |
| 2.02.03.01 | Deferred income and social contribution taxes | 101,356 | 82,211 |
| 2.02.04 | Provisions | 61,221 | 40,445 |
| 2.02.04.01 | Provisions for tax, civil and labor risks | 61,221 | 40,445 |
| 2.03 | Consolidated equity | 2,813,216 | 2,708,810 |
| 2.03.01 | Paid-in capital | 2,234,135 | 2,234,135 |
| 2.03.02 | Capital reserves | 50,217 | 49,727 |
| 2.03.02.02 | Special reserve for goodwill on merger | 65,366 | 65,427 |
| 2.03.02.04 | Granted options | 1,756 | 2,917 |
| 2.03.02.05 | Treasury Shares | (16,905) | (18,617) |
| 2.03.04 | Income reserves | 423,532 | 423,409 |
| 2.03.04.01 | Legal reserve | 30,128 | 30,128 |
| 2.03.04.05 | Retained profit reserve | 393,404 | 393,090 |
| 2.03.04.08 | Additional proposed dividend | - | 191 |
| 2.03.05 | Accumulated profit and losses | 103,837 | - |
| 2.03.06 | Other comprehensive income | 629 | 943 |
| 2.03.09 | Non-controlling interest | 866 | 596 |

Consolidated Quarterly Financial Information / Statement of Income

(R\$ in thousands)

| Code | Description | Current quarter 7/1/2014 to 9/30/2014 | Accumulated current period 1/1/2014 to 9/30/2014 | Current quarter 7/1/2013 to 9/30/2013 | Accumulated previous period 1/1/2013 to 9/30/2013 |
|------------|---|---|---|---|--|
| 3.01 | Revenue from products sold and/or services rendered | 727,847 | 2,077,393 | 646,171 | 1,859,091 |
| 3.02 | Cost of products sold and/or services rendered | (487,726) | 1,411,700 | (436,701) | (1,273,464) |
| 3.03 | Gross profit | 240,121 | 665,693 | 209,470 | 585,627 |
| 3.04 | Operating income/expenses | (152,819) | (436,712) | (125,047) | (370,860) |
| 3.04.02 | General and administrative expenses | (152,962) | (437,935) | (133,295) | (381,099) |
| 3.04.04 | Other operating income | 143 | 1,223 | 8,248 | 10,239 |
| 3.05 | Profit before financial income/expenses and taxes | 87,302 | 228,981 | 84,423 | 214,767 |
| 3.06 | Financial income/expenses | (21,704) | (74,758) | (27,347) | (66,441) |
| 3.06.01 | Financial income | 27,218 | 66,473 | 40,154 | 74,621 |
| 3.06.02 | Financial expenses | (48,922) | (141,231) | (67,501) | (141,062) |
| 3.07 | Income before income and social contribution taxes | 65,598 | 154,223 | 57,076 | 148,326 |
| 3.08 | Income and social contribution taxes | (21,964) | (50,056) | (21,084) | (53,602) |
| 3.08.01 | Current | (8,212) | (29,560) | (6,896) | (26,930) |
| 3.08.02 | Deferred | (13,752) | (20,496) | (14,188) | (26,672) |
| 3.09 | Net income from continuing operations | 43,634 | 104,167 | 35,992 | 94,724 |
| 3.11 | Consolidated net income for the period | 43,634 | 104,167 | 35,992 | 94,724 |
| 3.11.01 | Attributed to controlling shareholders | 43,507 | 103,837 | 35,910 | 94,591 |
| 3.11.02 | Attributed to non-controlling shareholders | 127 | 330 | 82 | 133 |
| 3.99 | Earnings per share (reais/share) | | | | |
| 3.99.01 | Basic earnings per share | | | | |
| 3.99.01.01 | Common shares | 0.14041 | 0.33521 | 0.11586 | 0.30493 |
| 3.99.02 | Diluted earnings per share | | | | |
| 3.99.02.01 | Common shares | 0.14033 | 0.33500 | 0.11574 | 0.30462 |

Consolidated Quarterly Financial Information / Statement of Comprehensive Income

(R\$ in thousands)

| Code | Description | Current quarter 7/1/2014 to 9/30/2014 | Accumulated current period 1/1/2014 to 9/30/2014 | Current quarter 7/1/2013 to 9/30/2013 | Accumulated previous period 1/1/2013 to 9/30/2013 |
|-------------|--|--|---|--|--|
| 4.01 | Consolidated net income for the period | 43,634 | 104,167 | 35,992 | 94,724 |
| 4.03 | Consolidated other comprehensive income for the period | 43,634 | 104,167 | 35,992 | 94,724 |
| 4.03.01 | Attributed to controlling shareholders | 43,507 | 103,837 | 35,910 | 94,591 |
| 4.03.02 | Attributed to non-controlling shareholders | 127 | 330 | 82 | 133 |

Consolidated Quarterly Financial Information / Statement of Cash Flows**(R\$ in thousands)**

| Code | Description | Accumulated current period 1/1/2014 to 9/30/2014 | Accumulated previous period 1/1/2013 to 9/30/2013 |
|-------------|---|---|--|
| 6.01 | Net cash from operating activities | 391,377 | 184,213 |
| 6.01.01 | Cash from operations | 386,565 | 299,589 |
| 6.01.01.01 | Net income for the period | 104,167 | 94,724 |
| 6.01.01.02 | Depreciation and amortization | 127,234 | 115,863 |
| 6.01.01.03 | Restatement of contingencies | 20,856 | 12,498 |
| 6.01.01.04 | Deferred taxes | 20,496 | 26,672 |
| 6.01.01.05 | Restatement of interest and exchange variation on loans | 116,122 | 79,281 |
| 6.01.01.06 | Gain on sale of property and equipment | 974 | 3,145 |
| 6.01.01.08 | Stock-option plan | 491 | 667 |
| 6.01.01.09 | Restatement of interest and exchange variation on marketable securities | (8,244) | (1,326) |
| 6.01.01.10 | Provision for disallowance and default | 4,469 | (31,935) |
| 6.01.02 | Changes in assets and liabilities | 20,584 | (95,280) |
| 6.01.02.01 | Increase in accounts receivable and other receivables | (114,076) | (62,166) |
| 6.01.02.02 | (Increase) Decrease in inventories | (5,802) | 3,906 |
| 6.01.02.03 | Increase in other current assets | (8,284) | (37,197) |
| 6.01.02.04 | Decrease (Increase) in other non-current assets | 60,854 | 17,786 |
| 6.01.02.05 | Increase in trade accounts payable | 22,051 | (5,867) |
| 6.01.02.06 | Increase in accounts payable and provisions | 65,841 | (11,742) |
| 6.01.03 | Other | (15,772) | (20,096) |
| 6.01.03.02 | Income and social contribution taxes paid | (15,772) | (20,096) |
| 6.02 | Net cash used in investing activities | (109,988) | (91,873) |
| 6.02.01 | Additions to property and equipment | (99,131) | (78,036) |
| 6.02.02 | Additions to intangible assets | (16,802) | (23,655) |
| 6.02.06 | Financial Applications | (20,338) | (494) |
| 6.02.09 | Proceeds from sale of property and equipment | 268 | 6,214 |
| 6.02.12 | Redemption of marketable securities for trading | 26,015 | 4,098 |
| 6.03 | Net cash used in financing activities | (300,665) | (98,099) |
| 6.03.01 | Loans received | 130,593 | 71,377 |
| 6.03.02 | Payment of loans | (320,983) | (101,934) |
| 6.03.06 | Dividends and interest on equity reserve paid | (31,372) | (20,500) |
| 6.03.07 | Interest paid | (78,903) | (47,042) |
| 6.05 | Decrease in cash and cash equivalents | (19,276) | (5,759) |
| 6.05.01 | At beginning of period | 535,881 | 228,519 |
| 6.05.02 | At end of period | 516,605 | 222,760 |

Consolidated Quarterly Financial Information / Statement of Changes in Equity - 1/1/2014 to 9/30/2014**(R\$ in thousands)**

| Code | Description | Paid-in Capital | Capital Reserve - Granted options and treasury shares | Income reserve | Retained earnings | Other comprehens ive income | Equity Attributable to Controlling Shareholders | Non- controlling interest | Consolidated Equity |
|-------------|-------------------------------|----------------------------|--|---------------------------|------------------------------|--|--|--|--------------------------------|
| 5.01 | Opening balances | 2,234,135 | 49,727 | 423,409 | - | 943 | 2,708,214 | 596 | 2,708,810 |
| 5.03 | Adjusted opening balances | 2,234,135 | 49,727 | 423,409 | - | 943 | 2,708,214 | 596 | 2,708,810 |
| 5.04 | Transaction with shareholders | - | 490 | - | - | - | 490 | - | 490 |
| 5.04.03 | Granted options | - | 490 | - | - | - | 490 | - | 490 |
| 5.05 | Total comprehensive income | - | - | - | 103,837 | - | 103,837 | 270 | 104,107 |
| 5.05.01 | Net income for the period | - | - | - | 103,837 | - | 103,837 | 330 | 104,167 |
| 5.05.02 | Others comprehensive income | - | - | - | - | - | - | (60) | (60) |
| 5.05.02.06 | Non-controlling interest | - | - | - | - | - | - | (60) | (60) |
| 5.06 | Internal changes in equity | - | - | 123 | - | (314) | (191) | - | (191) |
| 5.06.04 | Additional dividends paid | - | - | (191) | - | - | (191) | - | - |
| 5.06.05 | Depreciation of deemed cost | - | - | 314 | - | (314) | - | - | (191) |
| 5.07 | Closing balances | 2,234,135 | 50,217 | 423,532 | 103,837 | 629 | 2,812,350 | 866 | 2,813,216 |

Consolidated Quarterly Financial Information / Statement of Changes in Equity - 1/1/2013 to 9/30/2013**(R\$ in thousands)**

| Code | Description | Paid-in Capital | Capital Reserve, Granted options and treasury shares | Income reserve | Retained earnings | Other comprehens ive income | Equity Attributable to Controlling Shareholders | Non- controlling interest | Consolidated Equity |
|-------------|-------------------------------|----------------------------|---|---------------------------|------------------------------|--|--|--|--------------------------------|
| 5.01 | Opening balances | 2,234,135 | 48,171 | 322,933 | - | 1,571 | 2,606,810 | 382 | 2,607,192 |
| 5.03 | Adjusted opening balances | 2,234,135 | 48,171 | 322,933 | - | 1,571 | 2,606,810 | 382 | 2,607,192 |
| 5.04 | Transaction with shareholders | - | 666 | - | - | - | 666 | - | 666 |
| 5.04.03 | Granted options | - | 666 | - | - | - | 666 | - | 666 |
| 5.05 | Total comprehensive income | - | - | - | 94,591 | - | 94,591 | 133 | 94,724 |
| 5.05.01 | Net income for the period | - | - | - | 94,591 | - | 94,591 | 133 | 94,724 |
| 5.06 | Internal changes in equity | - | - | 202 | - | (471) | (269) | - | (269) |
| 5.06.04 | Depreciation of deemed cost | - | - | 471 | - | (471) | - | - | - |
| 5.06.05 | Additional dividends paid | - | - | (269) | - | - | (269) | - | (269) |
| 5.07 | Closing balances | 2,234,135 | 48,837 | 323,135 | 94,591 | 1,100 | 2,701,798 | 515 | 2,702,313 |

Consolidated Quarterly Financial Information / Statement of Value Added**(R\$ in thousands)**

| Code | Description | Accumulated current period 1/1/2014 to 9/30/2014 | Accumulated current period 1/1/2013 to 9/30/2013 |
|-------------|--|---|---|
| 7.01 | Revenue | 2,278,705 | 2,065,756 |
| 7.01.01 | Sale of goods, products and services | 2,277,610 | 2,055,677 |
| 7.01.02 | Other revenue | 1,223 | 10,239 |
| 7.01.04 | (Reversal of) allowance for doubtful accounts | (128) | (160) |
| 7.02 | Inputs acquired from third parties | (1,077,150) | (981,744) |
| 7.02.01 | Cost of products, goods and services sold | (779,882) | (711,741) |
| 7.02.02 | Materials, energy, third-party services and others | (297,268) | (270,003) |
| 7.03 | Gross value added | 1,201,555 | 1,084,012 |
| 7.04 | Retentions | (127,181) | (115,863) |
| 7.04.01 | Depreciation, amortization and depletion | (127,181) | (115,863) |
| 7.05 | Net value added produced | 1,074,374 | 968,149 |
| 7.06 | Transferred value added received | 66,473 | 74,621 |
| 7.06.02 | Financial income | 66,473 | 74,621 |
| 7.07 | Total value added to be distributed | 1,140,847 | 1,042,770 |
| 7.08 | Distribution of value added | 1,140,847 | 1,042,770 |
| 7.08.01 | Personnel | 509,540 | 455,484 |
| 7.08.02 | Taxes, fees and contributions | 283,769 | 259,056 |
| 7.08.03 | Debt remuneration | 243,371 | 233,506 |
| 7.08.04 | Equity remuneration | 104,167 | 94,724 |
| 7.08.04.03 | Retained profits | 103,837 | 94,591 |
| 7.08.04.04 | Non-controlling interest | 330 | 133 |

Comments on the Company's Performance

To the shareholders

2014 has been proving to be a very challenging year. Economic growth was expected to exceed 2%, but the updated forecast, as shown in the "Focus" Report issued by the Brazilian Central Bank on October 27, 2014, is about 0.3%, way below the growth rate reported over the past years.

During the third quarter of 2014, our growth rate started to stabilize. Although still impacted by the World Cup, we recovered a double-digit growth, reaching an increase of 11.7% over the third quarter of 2013.

As previously announced, on July 1, 2014, the following entities were merged into the Company: CDPI – Clínica de Diagnóstico por Imagem Ltda.; Clínica de Ressonância e Multi-Imagem Ltda.; Laboratórios Médicos Dr. Sergio Franco Ltda.; Imagem e Diagnósticos Ltda.; Multimagem PET Ltda. and Clínica de Ressonância e Multi-Imagem Caxias Ltda. In addition to simplifying the shareholding structure, the merger will have a positive impact on the Company's costs and streamline DASA's processes.

We kept our focus on improving the quality of our services. This improvement process comprises investment in recruiting and training our professionals, in modernizing and expanding our technology park and increasing our capability to process exams in our central laboratories. The main activities carried out in the third quarter of 2014 are as follows:

- Implementation of a Hospital Technical Center in the new "Hospital das Américas", which will be one of the most important hospital facility in Rio de Janeiro.
- Worldwide launch of Roche's new belt conveyor system in the Central Lab located in the Federal District (DF), expanding current output levels and allowing decentralization.
- Delboni International Symposium with 1000 registrations.
- 30 Doctors of Dasa group lectured at the Brazilian Congress of Radiology held in Rio de Janeiro.

Gross operating income

The Company's consolidated gross revenue for the third quarter of 2014 totaled R\$ 800.7 million, representing 11.7% increase against 3Q13, despite the adverse impact arising from the 2014 FIFA World Cup. For the nine-month period of 2014, gross revenue amounted to R\$ 2,277.6 million, a 10.8% increase when compared with the same period of 2013, when gross revenue totaled R\$ 2,055.7 million.

Based on the Company's gross revenue by service line, Lab-to-Lab market' (examination processing service for third-party laboratories) had the best performance in the quarter, earning R\$ 87.9 million and growing 14.9% against 3Q13 and representing 11.0% of Company's total revenue. For the nine-month period of 2014, revenue amounted to R\$ 248.6 million, a 15.9% increase when compared with the same period of 2013, totaling 10.9% of the Company's total revenue.

Revenue from outpatient market amounted to R\$ 596.6 million, a 14.5% increase when compared with the third quarter of 2013 and totaling 74.5% of the Company's total revenue. For the nine-month period of 2014, revenue totaled R\$ 1,682.4 million, an 12.2% increase when compared with the same period of 2013, totaling 73.9% of the Company's total revenue.

Revenue from hospital market amounted to R\$ 73.1 million, a 5.7% increase for the third quarter of 2014, thus representing 9.1% of the Company's total revenue. For the nine-month period of 2014, revenue was R\$ 212.6 million, a 5.9% increase when compared with the same period of 2013, totaling 9.3% of the Company's total revenue.

Revenue from public market amounted to R\$ 43.2 million, a 14.0% decrease in the 3Q14, thus accounting for 5.4% of the Company's revenue. For the nine-month period of 2014, revenue totaled R\$ 133.9 million, a 5.2% decrease when compared with the same period of 2013, totaling 5.9% of the Company's total revenue.

Costs and gross profit

In the third quarter of 2014, costs of services totaled R\$ 487.7 million, equivalent to 67.0% of net revenue, representing an increase of 11.7% against the third quarter of last year. In the third quarter of 2014, gross profit amounted to R\$ 240.1 million, increasing 14.6% against the third quarter of last year.

For the nine-month period of 2014, the cost of services rendered totaled R\$1,411.7 million, representing 68.0% of net revenue, an increase of 10.9%, when compared with the same prior year period. Gross profit was R\$ 665.7 million, a 13.7% increase when compared with the same prior year period.

Operating expenses

Operating expenses totaled R\$ 152.8 million in the third quarter of 2014, representing 21.0% of net revenue. There was an increase of 22.2% against the third quarter of 2013, in which operating expenses represented 19.4% of net revenue. For the nine-month period of 2014, operating expenses totaled R\$ 436.7 million, representing 21.0% of net revenue, a 17.8% increase when compared with the same prior year period.

EBITDA

In the third quarter of 2014, EBITDA amounted to R\$ 128.6 million, representing an increase of 6.5% against R\$ 120.7 million in the third quarter of last year. For this quarter, EBITDA margin was of 17.7%, when compared with the 18.7% margin of the third quarter of last year. For the nine-month period of 2014, we reached an EBITDA of R\$ 356.2 million, representing an increase of 7.7% against R\$330.6 million for the same prior year period.

| <i>In millions of reais</i> | 3Q14 | 3Q13 | Δ% | YTD 2014 | YTD 2013 | Δ% |
|--|--------------|--------------|-------------|--------------|--------------|-------------|
| Net income for the period | 43.6 | 36.0 | 21.2% | 104.2 | 94.7 | 10.0% |
| (+) Income and social contribution taxes | 22.0 | 21.1 | 4.2% | 50.1 | 53.6 | -6.6% |
| (+) Net financial expenses | 21.7 | 27.3 | -20.6% | 74.8 | 66.4 | 12.5% |
| (+) Depreciation and amortization | 41.3 | 36.3 | 13.8% | 127.2 | 115.8 | 9.8% |
| EBITDA (R\$ MM) | 128.6 | 120.7 | 6.5% | 356.2 | 330.6 | 7.7% |
| Ebitda margin | 17.7% | 18.7% | -1 p.a. | 17.1% | 17.8% | -0.6 p.a |

| Amounts in R\$ (in thousands) | Nine-month period ended 09/30/14 | Third quarter 2014 | Nine-month period ended 09/30/13 | Nine quarter 2013 |
|---|---|---------------------------|---|--------------------------|
| Income before income taxes | 154,222 | 65,598 | 148,326 | 57,076 |
| Adjustments: | | | | |
| Depreciation and amortization (Cost) | 81,017 | 26,683 | 75,024 | 22,921 |
| Depreciation and amortization (General and administrative expenses) | 46,164 | 14,604 | 40,800 | 13,369 |
| Financial income (expenses) | 74,758 | 21,704 | 66,441 | 27,347 |
| EBITDA | 356,162 | 128,589 | 330,591 | 120,712 |

Financial income (expenses)

In the third quarter of 2014, net financial expenses in the amount of R\$ 21.7 million were recorded against R\$ 27.3 million in the third quarter of 2013. The improved financial result was due to higher short-term investments with cash generated by the Company throughout 2014, management of the debt service cost, and lower foreign currency exposure.

In addition, in the third quarter of 2013, there was a positive impact of R\$ 2.7 million as a result of a financial gain from joining the Special Tax Installment Payment Program of the State of São Paulo (PEP) of ICMS debts, as well as a negative impact totaling R\$ 5.5 million referring to the repurchase of DASA Finance-issued Bonds. Both events are non-recurring events.

Income and social contribution taxes

The income and social contribution taxes account totaled R\$ 22.0 million for the quarter against R\$ 21.1 million in the third quarter of last year. For the nine-month of 2014, the taxes account accumulated R\$ 50.1 million, against R\$ 53.6 million in the same prior year period.

Net income

In the third quarter of 2014, net income totaled R\$43.6 million, 21.2% from the R\$36.0 million reported in the third quarter of last year. For the nine-month period of 2014, net income totaled R\$ 104.2 million, against R\$ 94.7 million in the same prior year period, an increase of 10.0%.

Cash and cash equivalents and short-term investments

Cash and cash equivalents and short-term investments at the end of the quarter totaled R\$592.2 million, allocated to: ensure the expansion and modernization of the existing units; open new units and replace imaging equipment; and improve the quality and payment of dividends.

Investments

In the third quarter of 2014, net investments in CAPEX amounted to R\$ 51.0 million. From January to September 2014, investments totaled R\$ 115.9 million. This year, investments will be particularly for: (i) implementing and developing production systems and supporting and renovating technology park, (ii) renovating and extending existing medical service units and new units, (iii) purchasing imaging equipment.

Indebtedness

Company's net debt totaled R\$ 729.7 million in 3Q14. 64.9% of gross indebtedness is allocated to long term and 6.0% refer to foreign currency debts. Foreign currency debt mostly comprises bank loans and equipment financing. Domestic currency debts mostly refer to debentures.

Significant events for the quarter

Merger of entities

On July 1, 2014, the Special Shareholders' Meeting unanimously and with no exceptions approved the merger of the Company's subsidiaries. (a) CDPI – Clínica de Diagnóstico por Imagem Ltda.; (b) Clínica de Ressonância e Multi-Imagem Ltda.; (c) Laboratórios Médicos Dr. Sergio Franco Ltda.; (d) Imagem e Diagnósticos Ltda.; (e) Multimagem PET Ltda.; and (f) Clínica de Ressonância e Multi-Imagem Caxias Ltda., with the consequent extinction of the entities merged, under the terms provided for in the Merger Protocol. The entities merged will be succeeded by the Company in all its rights and obligations, under the terms of article 227 of Law No. 6404/76 and article 1116 of the Brazilian Civil Code. Since the Company directly and indirectly holds total capital stock of the entities merged, (i) the Company will not increase capital nor issue new shares as a result of the merger, (ii) it is exempt from preparation of valuation report at market value as mentioned in article 264 of Law No. 6404/76, since the Company had already been exempted from compliance with this requirement by the Securities and Exchange Commission (CVM), and (iii) there will be no right to withdraw from the company due to the merger.

CADE Judgment – Cromossomo Participações II S/A

In a judgment session held on July 16, 2014, the Brazil's Administrative Council for Economic Defense (CADE) approved the acquisition by Cromossomo Participações II S/A of common shares issued by the Company, as a result of which Edson de Godoy Bueno and Dulce Pugliese de Godoy Bueno (shareholders owning, indirectly, all of the capital stock of Cromossomo), will control, directly and indirectly, more than 70% of the Company's capital stock, pursuant to Concentration Act No. 08700.002372/2014-07. Such approval by CADE was conditional upon compliance with an Agreement on Control of Concentrations (ACC).

The ACC is the equivalent mechanism under current antitrust law (Law No. 12529/11), as the old Performance Commitment Instrument applicable under Law No. 8884/94. Furthermore, according to information disclosed by CADE, the ACC obliges Cromossomo's shareholders to formally adhere to the obligations that had been provided for in the Performance Commitment Instrument the Company executed with CADE, in the official papers for Concentration Act nº 08012.010038/2010-4, which analyzed the association of DASA, MD1 Diagnósticos S.A. and others, as reported in a Material Fact notice disclosed by the Company on December 4, 2013.

The Company has not had access to any information other than that posted by CADE on the following link: <http://www.cade.gov.br/Default.aspx?1427f70110051b18e250e373cf74>

Change of Board of Directors members and Statutory Audit Committee

On July 24, 2014, the Board of Directors considered the request of resignation presented to the Company on July 17, 2014, by Mr. Mauricio Bittencourt Almeida Magalhaes, from the position of member of the Board of Directors to which he was elected at the Annual Shareholders' Meeting held on April 22, 2013, to hold office until the meeting to consider the closing balance sheet for 2014. On the same date, the Board of Directors approved the appointment of Marcelo Noll Barboza as a substitute for the position of Board of Directors member previously held by Maurício Bittencourt Almeida Magalhães, under the terms of paragraph 3, article 18 of the Company's Articles of Incorporation and article 150 of the Brazilian Corporation Law.

On the same date, the Board of Directors also considered the request of resignation presented by Sr. Maurício Bittencourt in the letter dated July 17, 2014, to the position of member of CAE to which he was elected at the Board of Director' Meeting held on April 22, 2013, and elected Marcelo Noll Barboza to substitute him, as a member with no specific denomination, for term of office up to April 21, 2023 – together with other CAE members.

Resignation and election of Directors

On July 24, 2014, the Board of Directors accepted Marcelo Rucker's request of resignation from the position of People Director, which will be extinguished. On the same date, Adriano Brito da Costa Lima was elected to the position of Vice-Chairman of Human Resources with the same powers previously assigned to the People Director, and Lilian Cristina Pacheco Lira to the position of Director of Risk Management, Compliance and Internal Control, to be held jointly with the position of Legal Director. Her attributions will comprise those addressed by law as well as to direct, manage, coordinate and supervise the area of risk management, compliance and internal controls, under a unified term of office with the other members of the Board until the Annual Shareholders' Meeting approving the accounts for fiscal year ending December 31, 2015.

The Vice Chairman of Human Resources will occupy the position of member of the Company's People Committee replacing Marcelo Rucker to fulfill his term of office until the Annual Shareholders' Meeting examining the financial statements for 2014, the reelection of which is allowed and may be extended up to the inauguration of their respective successors.

Perspectives for 2014

This year, the Company is increasing the number of opening of new units and the expansion of existing units so as to increase its capacity and quality of services.

We continue to intensify the relationship with physicians through seminars, visits and events in order to promote the exchange of ideas and knowledge of our physicians. With the purpose of increasing the perceived quality of our services, we will continue researching and creating techniques and studies that promote knowledge. We started revitalizing the Delboni brand, and this effort is extremely important to strengthen our presence in the São Paulo marketplace.

We effected the merger of the 6 entities into the Company, which will bring operating and tax synergies since the second quarter of 2014. We continue investing in the modernization of existing units, opening of new units, replacement of imaging equipment, together with greater investment to improve the quality of operations, will enable an environment more favorable to growth, based on the earnings for this year.

Projections and non-accounting data

The statements contained in this document, referring to business perspectives, projections on operating outcomes, financial income (expenses), and those related to the Company's expected growth, are only projections and, as such, based solely on Management's expectations for the future of the Company's businesses. This performance report includes accounting and non-accounting data, such as: operating and financial data, and projections based the Management's expectations. Non-accounting data were not subject to audit by the Company's independent auditors.

Representation of the Executive Board

Observing the provisions of CVM Ruling No. 480, we represent that we have discussed, reviewed and agreed with the quarterly information and with the independent auditor's review report issued on the respective quarterly information for the period ended September 30, 2014.

Acknowledgements

We thank our employees for their commitment, effort and talent, which enable us to obtain promising results and thank our customers and shareholders for their trust.

Notes to Quarterly Information

1. Operations

Diagnósticos da América S/A (Company) is a publicly-held corporation located in the city of Barueri, São Paulo State, with its registration granted by the Brazilian Securities Commission (CVM) for the trading of its securities on the stock market on November 5, 2004, and has been listed on the Novo Mercado segment of Bovespa since November 19, 2004, under code DASA3.

The Company's business purpose is to render services directly to individuals or through health insurance plans, insurance companies, medical-hospital assistance entities, other entities for healthcare financing, in the following areas: (i) clinical analysis, directly or through contracted laboratories; and (ii) other auxiliary diagnostic support services (SAD), exclusively through specialized clinics, as, for instance, in the following areas: a) cytology and pathologic anatomy; b) diagnostic by imaging and graphic methods; and c) nuclear medicine. As Management does not control them separately in their business process, they are not being recognized as reportable segments.

In addition, it explores activities related to: (i) tests in food and substances to evaluate risks for the human being; (ii) import, for its own use, of medical-hospital equipment, sets for diagnostics and related material in general; (iii) preparation, edition, publishing and distribution of newspapers, books, magazines, periodicals and other written media on scientific researches and activities developed by the Company; (iv) granting and administration of business franchising including advertising and publishing fund, training and selection of labor, supplying of equipment and research material suppliers, among others. The Company operates in lab-to-lab business (support to laboratories) through the Álvaro brand, and began offering services in the public health sector through the CientíficaLab brand. The Company can also hold equity interest in other entities.

The Company ended the third quarter of 2014 with 521 operating units, ambulatory and hospital:

| Brands | State | 9/30/2014 | 12/31/2013 |
|---------------------------------------|------------------------------|------------|------------|
| Delboni Auriemo (i) | São Paulo | 43 | 42 |
| Lavoisier | São Paulo | 79 | 77 |
| Bronstein | Rio de Janeiro | 41 | 41 |
| Lâmina (i) | Rio de Janeiro | 14 | 14 |
| Pasteur | Brasília | 25 | 25 |
| Frischmann | Paraná | 34 | 39 |
| Image | Bahia | 4 | 4 |
| Laboratório Álvaro | Paraná | 14 | 14 |
| LabPasteur | Ceará | 18 | 17 |
| Vita-Lâmina | Santa Catarina | 2 | 2 |
| Atalaia | Goiás | 22 | 22 |
| Exame | Brasília | 21 | 23 |
| MedImagem | Rio de Janeiro | 7 | 7 |
| Hospital Mãe de Deus | Rio Grande do Sul | 3 | 3 |
| Cedic/Cedilab | Mato Grosso | 10 | 9 |
| Unimagem | Ceará | 1 | 1 |
| CERPE | Pernambuco | 38 | 37 |
| Sérgio Franco | Rio de Janeiro | 80 | 80 |
| ProeCHO | Rio de Janeiro | 15 | 15 |
| Multi Imagem | Rio de Janeiro | 6 | 6 |
| CDPI | Rio de Janeiro | 7 | 7 |
| Previlab | São Paulo | 20 | 18 |
| Cytolab | São Paulo | 14 | 13 |
| Alta Excelência Diagnóstica – Premium | São Paulo and Rio de Janeiro | 3 | 3 |
| | | 521 | 519 |

(i) At September 30, 2014, the brand Club DA had 23 units, 19 of them linked to the brand Delboni Auriemo and 4 units linked to the brand Lâmina.

Notes to Quarterly Information

In addition, CientificaLab operates in the public healthcare segment, and the revenue arises from agreements entered into with customers in this segment. This operation ended the third quarter of 2014 with 28 clients, with exam requisitions totaling 1.5 million. CientificaLab has 591 collection units, 66 of them are hospitals and 525 ambulatory are Outpatient clinics not related to the units listed above.

The information above is not comprised by the scope of the independent auditors.

2. Performance Commitment Agreement (“PCA”)

At the trial session held on December 4, 2013, Merger Review Process No. 08012.010038/2010 was approved by CADE Administrative Court, under the terms of Reporting Member, with restrictions negotiated with the Company and formalized by means of the Performance Commitment Agreement (“PCA”).

With the execution of PCA, the Transaction Reversibility Preservation Agreement (“APRO”) executed by the Company on October 26, 2011, CADE considered this as completed, extinct and replaced by PCA, as it accomplished the objective of preserving the transaction reversibility nature.

Restrictions provided for by PCA are as follows:

- (i) The Company shall dispose assets in the cities located in the state of Rio de Janeiro, jointly totaling R\$ 110,000 of the revenue for the year for a single acquiring third party which (a) has no direct or indirect relationship with the Company; and (b) does not have more than 20% (twenty percent) of the relevant market of Medical Diagnosis Services (“MDS”) in the city of Rio de Janeiro;
- (ii) The Company, for the initial term of 3 (three) years, cannot conduct the operations described in items (a) to (c) below, involving MDS service providers in the cities of Duque de Caxias, Nilópolis, Niterói, Nova Iguaçu, Rio de Janeiro, São Gonçalo and Belford Roxo, in the relevant markets of: (a) clinical analysis, (b) pathology and cytopathology, (c) echocardiography, echocardiography, Doppler, ecovascular, Eco carotid and vertebral ecotransesophageal, (d) EEG, (e) CT (f) ultrasonography, (g) MRI, (h) bone densitometry and (i) mammogram:
 - (A) Merger or acquisition of company operating in MDS market (“merger/acquisition”);
 - (B) Direct or indirect acquisition, by purchase or exchange of shares, units of interest or securities convertible into shares, or tangible or intangible assets through contract or by any other mean, of the control or portion of one or more companies operating in the Medical Diagnosis Services (“MDS”) market; or
 - (C) execution of an association contract, consortium or joint venture with companies in the MDS market (“Association” and, together with merger/acquisition transactions, as defined above, “Qualifying Operations”).
- (iii) the Company cannot perform, for the initial term of 2 (two) years, any of the Qualifying Operations involving MDS companies in the cities of Guarulhos, Osasco, Santo André, São Bernardo do Campo, São Caetano do Sul, São Paulo and Taboão da Serra, in relevant markets of: (a) clinical analysis, (b) pathology and cytopathology (c) echocardiography, echocardiography, Doppler, ecovascular, eco-carotid, vertebral, and eco-transesophageal, (d) CT scan, (e) MRI, and (f) ultrasonography;

Notes to Quarterly Information

- (iv) the Company cannot perform, for the initial term of 2 (two) years, any of the Qualifying Operations involving MDS companies in the cities of Curitiba and São José dos Pinhais, in the relevant markets of: (a) clinical analysis, (b) CT and (c) ultrasonography;
- (v) after the initial three-year or two-year term, as the case may be, as determined in items (ii), (iii) and (iv) above, respectively, and for the additional term of two years after the initial term, the Company shall submit any Qualifying Operations to prior approval from CADE in the respective locations, even if the minimum billing standards provided by competition law for mandatory notification of merger procedures are not reached.

Observing the restrictions described above, MDS a) does not hinder the Company's, or any of its subsidiaries', corporate restructuring operations, either directly or indirectly; b) does not hinder acquisition of companies outside the cities mentioned above; and c) does not have provisions that may hinder the Company's organic growth.

The public version of Reporting Member, which influenced the decision of CADE Administrative Court, and exposes reason considered by CADE for the adopted decision, is available at www.cade.gov.br, as well as on the Company's investor relations website (www.dasa3.com.br).

Company management is carrying out the necessary actions to timely fulfil the obligations determined by CADE within TCD.

3. Consolidation procedures

The quarterly financial information comprises the financial information of the Company and the following subsidiaries:

| Direct Subsidiaries | Interest | 09/30/14 | 12/31/13 |
|--|--|--------------------------------|------------------|
| CDPI – Clínica de Diagnóstico por Imagem Ltda. (a) | Diagnósticos da América S.A. Laboratórios Médicos Dr. Sérgio Franco Ltda. (a) | - - | 99.99% 0.01% |
| Cientificalab Produtos Laboratoriais e Sistemas Ltda. | Diagnósticos da América S.A. DASA Real Estate Empreendimentos Imobiliários Ltda. | 82.90% 17.10% | 75.95% 24.05% |
| Clínica de Ressonância e Multi Imagem Ltda. (a) | Diagnósticos da América S.A. Laboratórios Médicos Dr. Sérgio Franco Ltda. (a) | - - | 99.99% 0.01% |
| Dasa Centro Oeste Participações Ltda. (d) | Diagnósticos da América S.A. DASA Real Estate Empreendimentos Imobiliários Ltda. | - - | 99.00% 1.00% |
| Dasa Finance Corporation | Diagnósticos da América S.A. | 100.00% | 100.00% |
| Dasa Log Empreendimentos Ltda. (d) | Diagnósticos da América S.A. DASA Real Estate Empreendimentos Imobiliários Ltda. | - - | 99.00% 1.00% |
| Dasa Nordeste Participações Ltda. (d) | Diagnósticos da América S.A. DASA Real Estate Empreendimentos Imobiliários Ltda. | - - | 99.00% 1.00% |
| Dasa Real Estate Empreendimentos Imobiliários Ltda. | Diagnósticos da América S.A. Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda. | 99.99% 0.01% | 99.99% 0.01% |
| Dasa Sudoeste Participações Ltda. (d) | Diagnósticos da América S.A. DASA Real Estate Empreendimentos Imobiliários Ltda. | - - | 99.00% 1.00% |
| Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda. | Diagnósticos da América S.A. Dr. Luciano Flávio Freitas de Almeida | 99.00% 1.00% | 99.00% 1.00% |

Notes to Quarterly Information

| Direct Subsidiaries | Interest | 09/30/14 | 12/31/13 |
|---|---|--|------------------------------------|
| Dasa Property Participações Ltda. | Diagnósticos da América S.A. DASA Real Estate Empreendimentos Imobiliários Ltda. | 99.00% 1.00% | 99.00% 1.00% |
| Laboratórios Médicos Dr. Sérgio Franco Ltda. (a) | Diagnósticos da América S.A. CDPI – Clínica de Diagnóstico por Imagem Ltda. (a) | - - | 99.99% 0.01% |
| Previlab Análises Clínicas Ltda. | Diagnósticos da América S.A. Alcione Moya Aprilante César Antônio Blázio | 99.65% 0.31% 0.04% | 99.55% 0.39% 0.06% |
| Pro Echo Cardiodata Serviços Médicos Ltda. (b) | Diagnósticos da América S.A. Laboratórios Médicos Dr. Sérgio Franco Ltda. (a) | 100% - | 69.58% 30.42% |
| LAFÊ Serviços Diagnósticos Ltda. | Diagnósticos da América S.A. Pro Echo Cardiodata Serviços Médicos Ltda. (b) CDPI – Clínica de Diagnóstico por Imagem Ltda. (a) | 99.99% 0.01% - | 99.98% 0.01% 0.01% |
| Clínica de Ressonância e Multi Imagem Petrópolis Ltda. (b) | Diagnósticos da América S.A. José Antonio Fragoço Borges Filho José Carlos de Castro Bersot Eduardo Luiz Primo de Siqueira | 70.00% 15.00% 7.50% 7.50% | - 15.00% 7.50% 7.50% |
| Check Up UP - Unidade Preventiva, Diagnóstico e Medicina Preventiva Ltda. | Diagnósticos da América S.A. | 100% | - |
| Indirect Subsidiaries | Interest | 09/30/14 | 12/31/13 |
| Check Up UP – Unidade Preventiva, Diagnóstico e Medicina Preventiva Ltda. (b) | CDPI – Clínica de Diagnóstico por Imagem Ltda. (a) Laboratórios Médicos Dr. Sérgio Franco Ltda. (a) | - - | 99.99% 0.01% |
| Clínica de Ressonância e Multi Imagem Caxias Ltda.(a) | Clínica de Ressonância Multi Imagem Ltda. (a) Laboratórios Médicos Dr. Sérgio Franco Ltda. (a) | - - | 99.99% 0.01% |
| Clínica de Ressonância e Multi Imagem Petrópolis Ltda.(b) | Clínica de Ressonância Multi Imagem Ltda.(a) José Antonio Fragoço Borges Filho José Carlos de Castro Bersot Eduardo Luiz Primo de Siqueira | - 15.00% 7.50% 7.50% | 70.00% 15.00% 7.50% 7.50% |
| Imagem e Diagnóstico Ltda.(a). | CDPI – Clínica de Diagnóstico por Imagem Ltda.(a) Laboratórios Médicos Dr. Sérgio Franco Ltda.(a) | - - | 99.99% 0.01% |
| Multimagem PET Ltda. (a) | CDPI – Clínica de Diagnóstico por Imagem Ltda. (a) Imagem e Diagnósticos Ltda. (a) | - - | 100.00% - |
| Stat Análises Clínicas Ltda. | Previlab Análises Clínicas Ltda. Alcione Moya Aprilante César Antônio Blázio Sanches | 99.66% 0.17% 0.17% | 99.66% 0.17% 0.17% |
| Incebrás Instituto Brasileiro da Coluna e do Cérebro Ltda. (c) | CDPI - Clínica de Diagnóstico por Imagem Ltda. (a) Jorge Alberto Costa e Silva Romeu Côrtes Domingues | - - - | 29.00% 70.00% 1.00% |

(a) At the Special Meeting (AGE) held on July 1, 2014, the following subsidiaries were merged into the Company: Laboratórios Médicos Dr. Sergio Franco Ltda. (**LSF**); CDPI – Clínica de Diagnóstico por Imagem Ltda. (**CDPI**); Clínica de Ressonância e Multi-Imagem Ltda. (**CRMI Rio**); Clínica de Ressonância e Multi-Imagem Caxias Ltda. (**CRMI Caxias**); Imagem e Diagnósticos Ltda. (**Imagem**); and Multimagem PET Ltda. (**MI Pet**).

Notes to Quarterly Information

The appraisal report was prepared by an expert firm based on the carrying amounts reported by the merged entities as at December 31, 2013. The merger was completed on July 7, 2014 based on the book values as at June 30, 2014, as follows:

| | LSF | CDPI | CRMI Rio | CRMI Caxias | Imagem | MI Pet | Total |
|--|----------------|----------------|-----------------|--------------------|---------------|---------------|----------------|
| Assets: | | | | | | | |
| Cash and cash equivalents | 19,384 | 50,045 | 164 | 1,899 | 663 | 5,634 | 77,789 |
| Trade accounts receivable | 100,161 | 44,408 | 8,207 | 424 | 23 | 1,478 | 154,701 |
| Inventories | 17,357 | 1,011 | 4 | - | - | - | 18,372 |
| Taxes recoverable | 9,316 | 10,582 | 2,386 | 208 | 12 | 160 | 22,664 |
| Investment | 38,820 | 7,882 | 5,383 | - | - | - | 52,085 |
| Property and equipment | 51,573 | 58,176 | 8,841 | 1,901 | 202 | 275 | 120,968 |
| Other receivables | 13,098 | 7,149 | 2,180 | 52 | 79 | 326 | 22,884 |
| | 249,709 | 179,253 | 27,165 | 4,484 | 979 | 7,873 | 469,463 |
| Liabilities | 96,661 | 93,371 | 10,653 | 957 | 102 | 871 | 202,615 |
| Net value of assets | 153,048 | 85,882 | 16,512 | 3,527 | 877 | 7,002 | 266,848 |
| | | | | | | | |
| | LSF | CDPI | CRMI Rio | CRMI Caxias | Imagem | MI Pet | Total |
| Cash flow from operating activities | 23,105 | (37,944) | 443 | 459 | 232 | 1,168 | (12,537) |
| Cash flow from investing activities | (6,772) | (6,294) | (316) | (20) | (26) | - | (13,428) |
| Cash flow from financing activities | (6,697) | 89,311 | (1,564) | (217) | (48) | (292) | 80,493 |
| | 9,636 | 45,073 | (1,437) | 222 | 158 | 876 | 54,528 |
| Cash and cash equivalents at beginning of period | 9,748 | 4,972 | 1,601 | 1,677 | 505 | 4,758 | 23,261 |
| Cash and cash equivalents at end of period | 19,384 | 50,045 | 164 | 1,899 | 663 | 5,634 | 77,789 |
| | 9,636 | 45,073 | (1,437) | 222 | 158 | 876 | 54,528 |

- (b) Entities that became the Company's direct subsidiaries after the merger completed on July 1, 2014, as mentioned in item (a) above.

Pursuant to a private agreement on corporate dissolution executed on April 30, 2014 (registered on August 15, 2014) by and among Jorge Alberto Costa e Silva, CDPI - Clínica de Diagnóstico por Imagem Ltda. (a Company's subsidiary merged on July 1, 2014) and Romeu Côrtes Domingues, the only partners in INCEBRAS Instituto Brasileiro da Coluna e do Cérebro Ltda., the parties decided in full and mutual consent, and in accordance with existing law, to dissolve and extinguish INCEBRAS. The entity became operational on November 12, 2009 and ceased all of its operations and activities on April 30, 2014, on a final and irrevocable basis, on the free will of the partners, who do not wish to continue the entity's activities. A closing balance sheet was prepared on April 30, 2014 for the liquidation and identification of assets that were distributed to the partners to the extent of their share in the entity's capital stock. The balance sheet did not identify any liabilities, with cash being the only asset identified in the amount of R\$ 9. This allowed executing the corporate dissolution with no liquidation period.

- (c) At the Board Meeting held on September 29, 2014, approval was given to termination, by means of liquidation and dissolution, of the Company's direct subsidiaries.

Notes to Quarterly Information

4. Basis for preparation of quarterly financial information

4.1. Statement of compliance (with respect to IFRS and CPC standards)

The quarterly financial information includes:

- The consolidated quarterly financial information prepared in accordance with CPC 21 (R1) and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).
- The Company's individual quarterly financial information prepared in accordance with CPC 21 (R1) - Interim Financial Reporting and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).

The issuance of the individual and consolidated quarterly financial information was authorized by the Board of Directors at the meeting held on November 10, 2014.

4.2. Basis for measurement

The individual and consolidated quarterly financial information were prepared on the basis of historical cost, with except for the following items recognized in the statement of financial position: derivative financial instruments measured at fair value; and (ii) non-derivative financial instruments measured at fair value thought profit or loss.

4.3. Functional and reporting currency

The preparation of the individual and consolidated quarterly financial information in accordance with IFRS and CPC standards requires Management to make judgments, estimates and assumptions that may affect the application of accounting policies and the reported values of assets, liabilities, revenue and expenses.

4.4. Use of estimates and judgment

The preparation of the individual and consolidated quarterly financial information in accordance with IFRS and with accounting practices adopted in Brazil requires Management to make judgments, estimates and assumptions that may affect the application of accounting policies and the reported values of assets, liabilities, revenue and expenses. Actual results may differ from such estimates.

Estimates and assumptions are permanently reviewed. Reviews relating to accounting estimates are recorded in the period in which the estimates are reviewed, as well as in any other future periods affected.

Uncertainties about the assumptions or estimates that may pose significant risks of material adjustments in future periods are detailed in the following notes:

- Note 5.8 - Impairment - mainly assumptions used in discounted cash flow estimates used for calculation of goodwill impairment;

Notes to Quarterly Information

- Note 9 - Trade accounts receivable, analysis of allowance for doubtful accounts considering disallowed amounts, default levels and returned checks;
- Note 19 - Provision for tax, social security, labor and civil risks;
- Note 21 - Income and social contribution taxes - deferred tax recovery analysis; and
- Note 24 - Assumptions used for determining the fair value of financial instruments.

5. Significant accounting practices

The Company represents that the Quarterly Financial Information (ITR) are presented in accordance with the accounting practices presented in Note 5 to the financial statements for the year ended December 31, 2013.

Many accounting practices and disclosures of the Company require the determination of fair value for financial and nonfinancial assets and liabilities. Fair value has been determined for measurement and/or disclosure purposes based on the methods disclosed in Note 6 to the financial statements for the year ended December 31, 2013 and should be reviewed together with these statements. If applicable, additional information on the assumptions used in determining fair value is disclosed in specific notes of the respective assets or liabilities.

Therefore, this quarterly financial information should be read jointly with the financial statements for the year ended December 31, 2013.

6. IFRS and CPC pronouncements and new legal requirements

6.1. New pronouncements that entered into force on January 1, 2014, but did not significantly impact the Company

- i) IAS 32 - Offsetting Financial Assets and Financial Liabilities - Amendments to IAS 32 - These amendments clarify the meaning of "currently has a legally enforceable right to set off the recognized known amounts" and the criterion that would cause settlement mechanisms that are not simultaneous (such as clearing house systems) to qualify for such offsetting.
- ii) Investment Entities (Amendments to IFRS 10, IFRS 12 and IAS 27) - These amendments introduce a consolidation exception for entities that meet the definition of 'investment entity' in IFRS 10. Under this exception, investment entities are required to measure their investments in subsidiaries at fair value through profit or loss.
- iii) IAS 39 - Novation of Derivatives and Continuation of Hedge Accounting - Amendments to IAS 39 - These amendments introduce an exception to the requirement to discontinuance of hedge accounting where a derivative, which is designated as hedging instrument, met certain conditions. The Company's policies not to act with derivative financial instrument transactions.
- iv) IFRIC 21 - Levies - It clarifies that an entity recognizes a liability for a levy when the activity that triggers payment, as identified by the relevant legislation, occurs. For a levy that is triggered upon reaching a given metric, the interpretation indicates that no liability should be recognized before the specified metric is reached.

Notes to Quarterly Information

6.2. New pronouncements not yet in effect, to become effective for annual periods beginning on or after January 1, 2015 for items i) and ii), and January 1, 2017, for item iii)

- i) IFRS 9 - Financial Instruments - It reflects the first phase of IASB's project to replace IAS 39 and applies to classification and measurement of financial assets and liabilities as defined by IAS 39. Initially, the pronouncement would become effective for annual periods beginning on or after January 1, 2013, but Amendments to IFRS 9: Mandatory Effective Date and Transition Disclosures, issued in December 2011, amended the effective date of IFRS 9 to annual periods beginning on or after January 1, 2015. In the subsequent phases, IASB will tackle issues such as hedge accounting and provision for impairment of financial assets. The Company does not expect that such standard causes a significant impact on its quarterly financial information.
- ii) IFRIC 21 - Levies - A liability to pay a levy should be recognized when the obligating event occurs.
- iii) IFRS 15 - Revenue from Contracts with Customers: establishes a five-step model that will apply to revenue earned from a contract with a customer, regardless of the type of revenue transaction or the industry. It applies to all revenue contracts and provides a model for recognizing and measuring gains and losses on the sale of some non-financial assets that are not an output of the entity's ordinary activities (e.g., sales of property, plant and equipment or intangibles). The standard will apply to annual periods beginning on or after January 1, 2017, and early adoption is permitted.

There are no other IFRS standards that are not yet into effect that may significantly impact the Company.

6.3. Provisional Executive Order No. 627 converted into law

In November 2013, Provisional Executive Order No. 627 was published and established that no taxation should be levied on profits and dividend calculated based on P&L computed between January 1, 2008 and December 31, 2013, by legal entities adopting the taxable profit, profit computed as a percentage of the Company's gross revenue, or arbitrated profit determined by the tax authorities, effectively paid through the publication date of the referred to Provisional Executive Order, at amounts exceeding those computed in light of the accounting methods and criteria in force as of December 31, 2007, provided that the taxpayer that has paid profit and dividend elected early adoption of the new tax regime as from 2014.

In May 2014, this Provisional Executive Order was converted into Law No. 12973, with amendment to some provisions of MP 672, including in connection with how to treat profits, dividend, interest on equity and investment measurement at equity pickup. Differently from the Provisional Executive Order, Law No. 12973 determined that no taxes are to be levied, unconditionally, on profit and dividend calculated based on P&L computed from January 1, 2008 to December 31, 2013.

The Company and its subsidiaries prepared studies on the effects that might arise from the application of Law No. 12973 provisions, and concluded that there are no material effects on its quarterly financial information as of September 30, 2014 and financial statements of December 31, 2013. The Company is assessing whether to elect early adoption of effects, and a decision will be expressed in the Federal Tax Debt and Credit Return (DCTF), regarding the triggering events occurring in the month of December 2014.

Notes to Quarterly Information

7. Cash and cash equivalents

| | Company | | Consolidated | |
|-----------------------|----------------|----------------|----------------|----------------|
| | 9/30/2014 | 12/31/13 | 9/30/2014 | 12/31/13 |
| Cash and banks | 9,579 | 14,826 | 16,831 | 20,868 |
| Marketable securities | 471,442 | 471,745 | 499,774 | 515,013 |
| | 481,021 | 486,571 | 516,605 | 535,881 |

Cash and cash equivalents classified in consolidated current assets are presented below:

| | 9/30/14 | | 12/31/13 | |
|--|----------------|------------------------------|----------------|----------------------------|
| | Amount | Average yield for the period | Amount | Average yield for the year |
| Cash and banks | 16,831 | - | 20,868 | - |
| Bank Deposit Certificate (CDB) / Repurchase agreements | 272,702 | 102.76% of CDI | 397,610 | 102.19% of CDI |
| Fixed income fund | 227,072 | 101.27% of CDI | 117,403 | 102.36% of CDI |
| | 516,605 | | 535,881 | |

Bank deposits represent balances in banks and immediate liquidity rights of which the use is not subject to any restrictions.

Marketable securities are readily redeemable from the issuer into a known cash amount and are subject to insignificant risk of change in value.

8. Marketable securities

| | Company | | | | | |
|-------------------------------|---------------|------------------------------|------------------------------|----------------------------|-----------------|----------------------------|
| | 9/30/14 | | 12/31/13 | | | |
| Currency | Amount (R\$) | Average yield for the period | Amount (R\$) | Average yield for the year | | |
| CDB/Repurchase agreements (a) | R\$ 8,882 | 102.76% of CDI | 6,393 | 100.01 of CDI | | |
| Fixed income fund (a) | R\$ 18,072 | 101.27% of CDI | 19,791 | 102.25% of CDI | | |
| Noncurrent assets | 26,954 | | 26,184 | | | |
| | Consolidated | | | | | |
| | 9/30/14 | | 12/31/13 | | | |
| Currency | Amount (US\$) | Amount (R\$) | Average yield for the period | Amount (US\$) | Amount (R\$) | Average yield for the year |
| CDB/Repurchase agreements (a) | R\$ - | 8,882 | 102.76% of CDI | - | 8,316 | 100.01% of CDI |
| Fixed income fund (a) | R\$ - | 28,448 | 101.27% of CDI | - | 29,477 | 102.25% of CDI |
| Corporate bonds (b) | US\$ 25,345 | 75,547 | 4.39% p.a. | 31,153 | 72,980 | 4.63% p.a. |
| | | 112,877 | | | 110,773 | |
| Current assets | | (75,547) | | | (72,980) | |
| Noncurrent assets | | 37,330 | | | 37,793 | |

(a) The consolidated amount of R\$37,330 (R\$37,793 at December 31, 2013) invested in fixed income funds and CDB / Committed transactions corresponds to guarantee for payment of contingencies that may be demanded from acquired companies, for a period of up to 6 years from the date of acquisition.

(b) Securities private companies acquired by subsidiary abroad.

Notes to Quarterly Information**9. Trade accounts receivable**

| | Company | | Consolidated | |
|--|------------------|-----------|------------------|-----------|
| | 9/30/2014 | 12/31/13 | 9/30/2014 | 12/31/13 |
| Trade notes receivable: | | | | |
| Falling due | 361,646 | 237,123 | 401,835 | 330,558 |
| Amounts overdue (b) | 180,321 | 127,425 | 222,276 | 187,579 |
| | 541,967 | 364,548 | 624,111 | 518,137 |
| Other accounts receivable: | | | | |
| Checks receivable | 395 | 456 | 534 | 795 |
| Bounced check | 1,416 | 808 | 1,583 | 1,469 |
| Credit card | 18,923 | 15,135 | 20,062 | 15,916 |
| Unbilled health plans (a) | 81,239 | 55,526 | 108,424 | 103,371 |
| | 101,973 | 71,925 | 130,603 | 121,551 |
| Total receivable: | 643,940 | 436,473 | 754,714 | 639,688 |
| Deducted of: | | | | |
| Allowance for doubtful accounts due to disallowance, default and returned checks | (55,738) | (46,318) | (71,955) | (67,486) |
| Adjustment to present value | - | - | (950) | - |
| | 588,202 | 390,155 | 681,809 | 572,202 |
| Current assets | (587,690) | (389,860) | (678,627) | (566,262) |
| Noncurrent assets | 512 | 295 | 3,182 | 5,940 |

(a) Refers to amounts of services rendered and not yet billed until to the closing of the period. Services not billed within 120 days are written off from account Agreements to be billed, adjusting profit or loss for the corresponding period.

(b) The aging of overdue balances is presented below:

| | % | Company | | | | | |
|-----------------|------|----------------|--------------------|----------------|--------------|--------------------|------------|
| | | 9/30/14 | | | 12/31/13 | | |
| | | Gross amount | Provision for loss | Net amount | Gross amount | Provision for loss | Net amount |
| 0 to 30 | | 65,511 | - | 65,511 | 37,685 | - | 37,685 |
| 31 to 60 | | 21,278 | - | 21,278 | 14,851 | - | 14,851 |
| 61 to 90 | | 15,445 | - | 15,445 | 11,914 | - | 11,914 |
| 91 to 120 | 25% | 12,187 | (3,047) | 9,140 | 6,957 | (1,739) | 5,218 |
| 121 to 180 | 50% | 13,288 | (6,644) | 6,644 | 12,536 | (6,268) | 6,268 |
| 181 to 360 | 75% | 31,920 | (23,939) | 7,981 | 23,918 | (17,939) | 5,979 |
| Over 360 | 100% | 20,692 | (20,692) | - | 19,564 | (19,564) | - |
| | | 180,321 | (54,322) | 125,999 | 127,425 | (45,510) | 81,915 |
| Returned checks | | 1,416 | (1,416) | - | 808 | (808) | - |
| | | 181,737 | (55,738) | 125,999 | 128,233 | (46,318) | 81,915 |

Notes to Quarterly Information

| | % | Consolidated | | | | | |
|-----------------|------|----------------|--------------------|----------------|--------------|--------------------|------------|
| | | 9/30/14 | | | 12/31/13 | | |
| | | Gross amount | Provision for loss | Net amount | Gross amount | Provision for loss | Net amount |
| 0 to 30 | | 74,787 | - | 74,787 | 52,629 | - | 52,629 |
| 31 to 60 | | 24,403 | - | 24,403 | 22,667 | - | 22,667 |
| 61 to 90 | | 19,587 | - | 19,587 | 18,091 | - | 18,091 |
| 91 to 120 | 25% | 19,265 | (4,816) | 14,449 | 13,513 | (3,378) | 10,135 |
| 121 to 180 | 50% | 19,732 | (9,866) | 9,866 | 17,964 | (8,982) | 8,982 |
| 181 to 360 | 75% | 35,248 | (26,436) | 8,812 | 36,232 | (27,174) | 9,058 |
| Over 360 | 100% | 29,254 | (29,254) | - | 26,483 | (26,483) | - |
| | | 222,276 | (70,372) | 151,904 | 187,579 | (66,017) | 121,562 |
| Returned checks | | 1,583 | (1,583) | - | 1,469 | (1,469) | - |
| | | 223,859 | (71,955) | 151,904 | 189,048 | (67,486) | 121,562 |

The collection process for diagnostic support services provided by the Company is complex due to a variety of factors, including the large number of health plans used and different coverage offered. This complexity has historically given rise to loss due to disallowances. To a lesser extent, there are also losses due to default.

Disallowances mainly refer to: (i) operating issues, such as services rendered to customers of health care plans without previous authorization; (ii) sales issues, such as new price lists agreed, which have not been updated on both systems; and (iii) technical issues, such as different interpretations of examination requisitions.

To cover the losses as a result of such disallowances and default, the Company adopts the policy of recording a provision for losses from disallowances and default based on receivables overdue for more than 90 days, as shown below:

| Overdue receivables | % of provision |
|---------------------|----------------|
| 91 and 120 days | 25% |
| 121 and 180 days | 50% |
| 181 and 360 days | 75% |
| Above 360 days | 100% |

For the nine-month period ended September 30, 2014, losses arising from disallowance and default represented 2.5% of gross operating revenue (3.7% in the nine-month period ended September 30, of 2013).

From 2012 onwards, the Company started to write-off trade notes overdue for more than 2 years against provision. Accordingly, in the nine-month period ended September 30 of 2014, R\$ 13,425 (R\$ 57,969 in the in the nine-month period ended September 30 of 2013) were written off.

The Company also records provisions for all bad checks, corresponding to, at September 30, 2014, R\$ 1,416 (R\$ 808 at December 31, 2013) in Company and to R\$ 1,583 (R\$ 1,469 at December 31, 2013) in Consolidated.

Given that receivables from credit cards companies are historically fully paid, the Company has not set up an allowance for losses in this account.

Notes to Quarterly Information

Changes in allowances for doubtful accounts due to disallowance, default and returned checks due to insufficient funds, for 2014 in the nine-month period ended September 30 in consolidated, is as follows:

| | | | |
|---|--|--------------|-----------------|
| Balance at December 31, 2013 | | | <u>(67.486)</u> |
| Change in consolidated provision | | | |
| Allowance for doubtful accounts due to disallowance and default | | (57.974) (a) | |
| Reversal of allowance for disallowance and default due to payment and resources proper disallowance | | 40.194 | |
| Derecognition of provision for receivables overdue for more than 2 years | | 13.425 | |
| Reversal of provision for returned checks | | (114) | (4.469) |
| Balance at September 30, 2014 | | | <u>(71.955)</u> |

(a) Loss for the nine-month period ended September 30, 2014, as disclosed in Note 27.

10. Inventories

| | Company | | Consolidated | |
|-------------------------------|----------------|-----------------|---------------------|-----------------|
| | 9/30/14 | 12/31/13 | 9/30/14 | 12/31/13 |
| Direct material - domestic | 34,887 | 23,643 | 38,428 | 35,406 |
| Direct material - imported | 8,493 | 5,593 | 9,000 | 7,664 |
| Secondary material - domestic | 11,574 | 7,857 | 12,762 | 11,496 |
| Supplies | 5,579 | 3,881 | 6,204 | 5,836 |
| Provision for obsolescence | (1,076) | (568) | (1,209) | (1,019) |
| | 59,457 | 40,406 | 65,185 | 59,383 |

11. Taxes recoverable

| | Company | | Consolidated | |
|--|----------------|-----------------|---------------------|-----------------|
| | 9/30/14 | 12/31/13 | 9/30/14 | 12/31/13 |
| Income and social contribution taxes (IR/CS) - withholding income tax | 19,265 | 6,911 | 23,191 | 10,607 |
| IR/CS - prepaid amounts of the period | 7,459 | - | 10,112 | - |
| IR/CS - credits recoverable | 58,933 | 63,222 | 67,516 | 83,861 |
| Contribution Tax on Gross Revenue for Social Integration Program (PIS) and Contribution Tax on Gross Revenue for Social Security Financing (COFINS) - withholding income tax | 28,009 | 19,437 | 30,284 | 27,214 |
| Service Tax (ISS) - withholding income tax | 7,642 | 5,385 | 14,154 | 13,653 |
| National Institute for Social Security (INSS) recoverable | 7,850 | 6,089 | 29,764 | 27,502 |
| Other | 7,212 | 6,255 | 7,571 | 6,859 |
| | 136,370 | 107,299 | 182,592 | 169,696 |

Notes to Quarterly Information**12. Investments****12.1. Information on investments in subsidiaries**

| | Company | | Consolidated | |
|---|----------------|----------------|--------------|------------|
| | 9/30/14 | 12/31/13 | 9/30/14 | 12/31/13 |
| DASA Real Estate Empreendimentos Imobiliários Ltda. | 28,787 | 29,733 | - | - |
| CientificaLab Produtos Laboratoriais e Sistemas Ltda. | 107,321 | 85,981 | - | - |
| Instituto de Endocrinologia e Medicina Nuclear do Recife S.A. (CERPE) | 39,787 | 33,543 | - | - |
| CDPI - Clínica de Diagnóstico por Imagem Ltda. (d) | - | 47,368 | - | - |
| CRMI - Clínica de Ressonância e Multi Imagem Ltda. (d) | - | 16,102 | - | - |
| Pro Echo Cardiodata Serviços Médicos Ltda. (e) | 44,884 | 88,079 | - | - |
| Laboratórios Médicos Dr. Sérgio Franco Ltda. (d) | - | 122,884 | - | - |
| Previlab - Análises Clínicas Ltda. | 34,909 | 25,813 | - | - |
| DASA Finance Corporation | 7,278 | 2,795 | - | - |
| Clínica de Ressonância e Multi Imagem Petrópolis Ltda. (e) | 1,965 | - | - | - |
| LAFÊ Serviços Diagnósticos Ltda. | 5,037 | - | - | - |
| Dasa Property Participações Ltda. | 53 | 52 | - | - |
| Dasa Nordeste Participações Ltda | 52 | 51 | - | - |
| Dasa Centro Oeste Participações Ltda. | 52 | 51 | - | - |
| Dasa Sudoeste Participações Ltda. | 52 | 51 | - | - |
| | 270,177 | 452,503 | - | - |
| Other investments | 679 | 624 | 799 | 786 |
| | 270,856 | 453,127 | 799 | 786 |

| Subsidiary | Reporting date | Number of units of interest/ shares | Number of unites of interest/ shares held | Interest in paid-in capital (%) | Paid-in capital | Equity | Profit for the period |
|---------------------------------|----------------|-------------------------------------|---|---------------------------------|-----------------|---------|-----------------------|
| DASA Real Estate | 09/30/2014 | 25,667,079 | 25,667,078 | 99.99 | 25,667 | 28,787 | (946) |
| | 12/31/2013 | 25,667,079 | 25,667,078 | 99.99 | 25,667 | 29,733 | (836) |
| CientificaLab | 09/30/2014 | 108,176,629 | 89,676,628 | 82.90 | 97,177 | 107,321 | (3,660) |
| | 12/31/2013 | 70,676,629 | 53,676,628 | 75.95 | 70,677 | 85,981 | (12,536) |
| DASA Finance Corp | 09/30/2014 | 18,550,000 | 18,550,000 | 100.00 | 41,123 | 7,277 | 4,482 |
| | 12/31/2013 | 50,000 | 50,000 | 100.00 | 41,123 | 2,795 | (12,117) |
| CERPE | 09/30/2014 | 122,024 | 120,804 | 99.00 | 122 | 39,787 | 7,302 |
| | 12/31/2013 | 122,024 | 120,804 | 99.00 | 122 | 33,543 | 4,544 |
| CDPI (d) | 09/30/2014 | - | - | - | - | - | 7,244 |
| | 12/31/2013 | 1,834,280 | 1,834,279 | 99.99 | 18,343 | 47,368 | 8,909 |
| CRMI (d) | 09/30/2014 | - | - | - | - | - | 2,376 |
| | 12/31/2013 | 2,508,000 | 2,507,999 | 99.99 | 2,508 | 16,102 | 5,694 |
| Pro Echo (e) | 09/30/2014 | 47,483,058 | 47,483,058 | 100.00 | 47,483 | 44,884 | 2,022 |
| | 12/31/2013 | 131,483,058 | 91,483,058 | 69.58 | 131,483 | 126,587 | 4,165 |
| Lab. Méd. Dr. Sérgio Franco (d) | 09/30/2014 | - | - | - | - | - | 40,792 |
| | 12/31/2013 | 63,902,082 | 63,902,081 | 99.99 | 63,902 | 122,884 | 69,184 |
| Previlab | 09/30/2014 | 29,613,314 | 29,509,743 | 99.65 | 29,613 | 34,910 | 2,885 |
| | 12/31/2013 | 23,113,314 | 23,009,743 | 99.56 | 23,113 | 25,813 | 2,778 |
| CRMI Petrópolis (d) | 09/30/2014 | 1,080,222 | 756,155 | 70.00 | 1,080 | 1,965 | 295 |
| | 31/12/2013 | - | - | - | - | - | - |

Notes to Quarterly Information

| Subsidiary | Reporting date | Number of units of interest/ shares | Number of unites of interest/ shares held | Interest in paid-in capital (%) | Paid-in capital | Equity | Profit for the period |
|----------------------------------|--------------------------|-------------------------------------|---|---------------------------------|-----------------|------------|-----------------------|
| LAFÊ Serviços Diagnósticos Ltda. | 09/30/2014 12/31/2013 | 6,376,316 10,000 | 6,376,216 9,900 | 99.00 99.00 | 6,376 - | 5,037 - | (1,339) - |
| Dasa Property Part. | 09/30/2014 12/31/2013 | 50,000 50,000 | 49,500 49,500 | 99.00 99.00 | 50 50 | 53 52 | 2 2 |
| Dasa Nordeste Part. | 09/30/2014 12/31/2013 | 50,000 50,000 | 49,500 49,500 | 99.00 99.00 | 50 50 | 52 51 | 2 1 |
| Dasa Centro Oeste Part. | 09/30/2014 12/31/2013 | 50,000 50,000 | 49,500 49,500 | 99.00 99.00 | 50 50 | 52 51 | 1 1 |
| Dasa Sudoeste Part. | 09/30/2014 12/31/2013 | 50,000 50,000 | 49,500 49,500 | 99.00 99.00 | 50 50 | 52 51 | 1 1 |

12.2. Changes in investments

| | December 31, 2013 | Capital increase (reduction) | Partial split-off | Proposed and prepaid dividends (c) | Interest on equity | Merge of Subsidiaries | Equity pickup | September 30, 2014 |
|---------------------------------|-------------------|------------------------------|-------------------|------------------------------------|--------------------|-----------------------|---------------|--------------------|
| DASA Real Estate | 29,733 | - | - | - | - | - | (946) | 28,787 |
| CientíficaLab | 85,981 | 25,000 | - | - | - | - | (3,660) | 107,321 |
| CERPE | 33,543 | - | - | (1,058) | - | - | 7,302 | 39,787 |
| CDPI (a) | 47,368 | 36,500 | - | (2,227) | (3,004) | (85,881) | 7,244 | - |
| CRMI | 16,102 | - | - | (1,423) | (543) | (16,512) | 2,376 | - |
| Pro Echo (e) | 88,079 | (84,000) | - | - | - | 38,783 | 2,022 | 44,884 |
| Lab. Méd. Dr. Sérgio Franco (b) | 122,884 | - | (6,366) | - | (4,262) | (153,048) | 40,792 | - |
| Previlab (a) | 25,813 | 6,500 | - | (288) | - | - | 2,885 | 34,910 |
| DASA Finance Investimentos | 2,795 | - | - | - | - | - | 4,482 | 7,277 |
| CRMI Petrópolis (e) | - | - | - | (186) | - | 1,856 | 295 | 1,965 |
| Lafê Serviços Diagnósticos (b) | - | 10 | 6,366 | - | - | - | (1,339) | 5,037 |
| Dasa Property Part. (f) | 52 | - | - | (1) | - | - | 2 | 53 |
| Dasa Nordeste Part. (f) | 51 | - | - | (1) | - | - | 2 | 52 |
| Dasa Centro Oeste Part. (f) | 51 | - | - | - | - | - | 1 | 52 |
| Dasa Sudoeste Part. (f) | 51 | - | - | - | - | - | 1 | 52 |
| | 452,503 | (15,990) | - | (5,184) | (7,809) | (214,802) | 61,459 | 270,177 |
| Check-UP (negative equity) | - | - | - | - | - | (3,747) | (594) | (4,341) |
| | 452,503 | (15,990) | - | (5,184) | (7,809) | (218,549) | 60,865 | 265,836 |

(a) Capital payment

CDPI - On February 3, 2014, the Company subscribed and paid 36,500,000 new units of interest of subsidiary CDPI, equivalent to R\$ 36,500, based on the 28th amendment to the Articles of Organization of CDPI, this subsidiary was later merged into the Company, please refer to item 12.2 (e) below.

PREVILAB - On February 3, 2014, the Company subscribed and paid 6,500,000 new units of interest of subsidiary PREVILAB, equivalent to R\$ 6,500, based on the 16th amendment to the Articles of Organization of PREVILAB.

(b) Partial split-off

In a meeting held on February 28, 2014 of the partners of subsidiary Laboratórios Médicos Dr. Sérgio Franco Ltda. (Sérgio Franco), it was decided to:

- i Confirm the appointment and engagement of APSIS Consultoria e Avaliações Ltda. to measure, at carry amount value, split-off equity of Sérgio Franco, at December 31, 2013, transferred to Lafê Serviços Diagnósticos Ltda. (Lafê), at February 28, 2014, based on an unqualified approval of the appraisal report, whereby equity of part of Sérgio Franco transferred to Lafê was determined, amounting to R\$ 6,366, comprised by cash and cash equivalents amounting to R\$ 4,000 and assets related to the business units (establishments) thereof, amounting to R\$ 2,366. Equity of subsidiary Sérgio Franco was measured at carry amount value, which took into consideration the accounting records of the balance sheet at December 31, 2013.

Notes to Quarterly Information

- ii. Approve the "Rationale for Partial Split-off of Laboratórios Médicos Dr. Sérgio Franco Ltda. following the Merger of Net Assets Split Off by Lafê Serviços Diagnósticos Ltda.";
- iii. Approve, with no reserves, the Partial Split-off of subsidiary Sérgio Franco and merger of net assets split off by Lafê;
- iv. Approve capital decrease of subsidiary Sérgio Franco amounting to R\$ 6,366, corresponding to net assets split off, from R\$ 63,902 to R\$ 57,536, due to the cancellation of 6,366,316 units of interest of the company. By virtue of such decrease, capital of subsidiary Sérgio Franco now amounts to R\$ 57,536.
- (c) Proposed and prepaid dividends
- Proposed dividends amount to R\$ 4,887, corresponding to net income in 2013, and prepaid dividends in the amount of R\$ 293, related to the related to the nine-month period ended September 30 of 2014.
- (d) Merger of subsidiaries
- At the Special Meeting (AGE) held on July 1, 2014, the following subsidiaries were merged into the Company: CDPI – Clínica de Diagnóstico por Imagem Ltda.; Clínica de Ressonância e Multi-Imagem Ltda.; Laboratórios Médicos Dr. Sergio Franco Ltda.; Imagem e Diagnósticos Ltda.; Multimagem PET Ltda.; and Clínica de Ressonância e Multi-Imagem Caxias Ltda.
- (e) Following the merger completed on July 1, 2014, the Company has held direct control over Pro Echo Cardiodata Ltda., with interest being increased from 69.58% to 100%, and CRMI Petrópolis in which the Company had no interest and now holds a 70% stake therein.
- (f) At the Board Meeting held on September 29, 2014, approval was given to termination, by means of liquidation and dissolution, of the Company's direct subsidiaries.

13. Property and equipment, net

| | Average depreciation rate % p.a. | Company | | | |
|--------------------------|----------------------------------|------------------|--------------------------|----------------|----------------|
| | | 9/30/14 | | | 12/31/13 |
| | | Cost | Accumulated depreciation | Net | Net |
| Properties | 4 | 1,426 | (890) | 536 | 576 |
| Leasehold improvements | 10 | 470,424 | (249,221) | 221,203 | 141,761 |
| Machinery and equipment | 12 | 476,799 | (221,741) | 255,058 | 193,105 |
| Furniture and fixtures | 11 | 65,914 | (29,694) | 36,220 | 28,526 |
| Facilities | 10 | 56,349 | (19,763) | 36,586 | 17,371 |
| IT equipment | 20 | 146,049 | (87,251) | 58,798 | 52,753 |
| Vehicles | 20 | 4,143 | (3,396) | 747 | 835 |
| Library | 10 | 184 | (125) | 59 | 21 |
| Land | - | 180 | - | 180 | 180 |
| Acquisitions in progress | - | 29,937 | - | 29,937 | 107,954 |
| | | 1,251,405 | (612,081) | 639,324 | 543,082 |

| | Average depreciation rate % p.a. | Consolidated | | | |
|--------------------------|----------------------------------|------------------|--------------------------|----------------|----------------|
| | | 9/30/14 | | | 12/31/13 |
| | | Cost | Accumulated depreciation | Net | Net |
| Properties | 4 | 5,166 | (2,070) | 3,096 | 3,248 |
| Leasehold improvements | 10 | 491,568 | (258,108) | 233,460 | 196,010 |
| Machinery and equipment | 12 | 517,839 | (243,500) | 274,339 | 260,153 |
| Furniture and fixtures | 11 | 73,735 | (33,083) | 40,652 | 37,500 |
| Facilities | 10 | 60,420 | (21,095) | 39,325 | 36,330 |
| IT equipment | 20 | 155,702 | (94,682) | 61,020 | 57,979 |
| Vehicles | 20 | 5,606 | (4,793) | 813 | 978 |
| Library | 10 | 203 | (137) | 66 | 76 |
| Land | - | 6,574 | - | 6,574 | 6,574 |
| Acquisitions in progress | - | 32,967 | - | 32,967 | 121,332 |
| | | 1,349,780 | (657,468) | 692,312 | 720,180 |

Notes to Quarterly InformationChanges in cost

| | Company | | | | | 9/30/14 |
|--------------------------|-------------------------------|--|------------------|-------------------|------------------------------|------------------|
| | Changes for the period | | | | | |
| | 12/31/13 | Addition by incorporation (a) | Additions | Write-offs | Transferences (b) | |
| Properties | 1,426 | - | - | - | - | 1,426 |
| Leasehold improvements | 344,738 | 65,465 | 20,865 | (1,021) | 40,377 | 470,424 |
| Machinery and equipment | 357,011 | 78,068 | 37,140 | (2,375) | 6,955 | 476,799 |
| Furniture and fixtures | 51,900 | 6,906 | 3,384 | (155) | 3,879 | 65,914 |
| Facilities | 27,596 | 22,340 | 4,692 | (117) | 1,838 | 56,349 |
| IT equipment | 120,717 | 8,028 | 8,152 | (426) | 9,578 | 146,049 |
| Vehicles | 4,112 | - | 99 | (68) | - | 4,143 |
| Library | 117 | 67 | - | - | - | 184 |
| Land | 180 | - | - | - | - | 180 |
| Construction in progress | 107,954 | 2,165 | 11,542 | - | (91,724) | 29,937 |
| | 1,015,751 | 183,039 | 85,874 | (4,162) | (29,097) | 1,251,405 |

| | Consolidated | | | | 9/30/14 |
|--------------------------|-------------------------------|------------------|-------------------|------------------------------|------------------|
| | Changes for the period | | | | |
| | 12/31/13 | Additions | Write-offs | Transferences (b) | |
| Properties | 5,166 | - | - | - | 5,166 |
| Leasehold improvements | 422,952 | 24,536 | (1,020) | 45,100 | 491,568 |
| Machinery and equipment | 467,377 | 44,743 | (2,451) | 8,170 | 517,839 |
| Furniture and fixtures | 65,332 | 3,907 | (31) | 4,527 | 73,735 |
| Facilities | 53,383 | 5,066 | (98) | 2,069 | 60,420 |
| IT equipment | 135,714 | 9,104 | (406) | 11,290 | 155,702 |
| Vehicles | 6,156 | 133 | (683) | - | 5,606 |
| Library | 203 | - | - | - | 203 |
| Land | 6,574 | - | - | - | 6,574 |
| Acquisitions in progress | 121,332 | 11,642 | 295 | (100,302) | 32,967 |
| | 1,284,189 | 99,131 | (4,394) | (29,146) | 1,349,780 |

(a) Merger of the Company's subsidiaries, as mentioned in Note 3.

(b) Expenses made by the Company classified under Construction in progress for the build-up, implementation and development period of certain establishments, which are transferred to a specific account of fixed or intangible assets when the assets are ready for use.

Notes to Quarterly InformationChanges in accumulated depreciation

| | Company | | | | | |
|-------------------------|-------------------------------|--|------------------|-------------------|------------------------------|------------------|
| | Changes for the period | | | | | |
| | 12/31/13 | Addition by incorporation (a) | Additions | Write-offs | Transferences (b) | 9/30/14 |
| Properties | (850) | - | (40) | - | - | (890) |
| Leasehold improvements | (202,977) | (19,552) | (27,253) | 561 | - | (249,221) |
| Machinery and equipment | (163,906) | (30,227) | (29,268) | 1,570 | 90 | (221,741) |
| Furniture and fixtures | (23,374) | (1,927) | (4,506) | 106 | 7 | (29,694) |
| Facilities | (10,225) | (6,887) | (2,679) | 28 | - | (19,763) |
| IT equipment | (67,964) | (3,456) | (16,210) | 411 | (32) | (87,251) |
| Vehicles | (3,277) | - | (187) | 68 | - | (3,396) |
| Library | (96) | (23) | (6) | - | - | (125) |
| | (472,669) | (62,072) | (80,149) | 2,744 | 65 | (612,081) |

| | Consolidated | | | | |
|-------------------------|-------------------------------|------------------|-------------------|----------------------|------------------|
| | Changes for the period | | | | |
| | 12/31/13 | Additions | Write-offs | Transferences | 9/30/14 |
| Properties | (1,918) | (152) | - | - | (2,070) |
| Leasehold improvements | (226,942) | (31,727) | 561 | - | (258,108) |
| Machinery and equipment | (207,224) | (37,967) | 1.604 | 87 | (243,500) |
| Furniture and fixtures | (27,832) | (5,366) | 109 | 6 | (33,083) |
| Facilities | (17,053) | (4,069) | 27 | - | (21,095) |
| IT equipment | (77,735) | (17,311) | 392 | (28) | (94,682) |
| Vehicles | (5,178) | (173) | 558 | - | (4,793) |
| Library | (127) | (10) | - | - | (137) |
| | (564,009) | (96,775) | 3,251 | 65 | (657,468) |

(a) Merger of the Company's subsidiaries, as mentioned in Note 3.

(b) Expenses made by the Company classified under Construction in progress for the build-up, implementation and development period of certain establishments, which are transferred to a specific account of fixed or intangible assets when the assets are ready for use.

Additions to accumulated depreciation, stated in changes for the property and equipment items, were partly recorded under general and administrative expenses and partly under costs of goods and/or services sold.

During the period, the Company did not identify any assets impairment indicator, and also did not capitalize interest.

Notes to Quarterly Information**14. Intangible assets**

| | Average amortization rate %p.a. | Company | | | | | |
|--|---|------------------|-----------------------------|------------------|-----------|-----------------------------|-----------|
| | | 9/30/14 | | | 12/31/13 | | |
| | | Cost | Accumulated Amortization | Net | Cost | Accumulated amortization | Net |
| Acquisition of interest - Goodwill | | 2,123,084 | (145,442) | 1,977,642 | 2,116,170 | (141,766) | 1,974,404 |
| Other intangible assets | | | | | | | |
| IT systems | 20 | 198,214 | (119,888) | 78,326 | 151,836 | (97,167) | 54,669 |
| Commercial area use right | 20 | 1,433 | (717) | 716 | 1,203 | (592) | 611 |
| Other intangible assets | 20 | 12,628 | (4,249) | 8,379 | 12,628 | (4,249) | 8,379 |
| System implementation project | 20 | 12,293 | (12,293) | - | 12,293 | (12,293) | - |
| Project development | 33 | 10,259 | (10,166) | 93 | 10,259 | (10,166) | 93 |
| Brands | 3,3 | 236,037 | (29,740) | 206,297 | 236,037 | (23,360) | 212,677 |
| Exclusive agreement with customers - Unimagem | 10 | 9,403 | (5,109) | 4,294 | 9,403 | (4,704) | 4,699 |
| Relationship with hospitals | 5 | 35,748 | (6,975) | 28,773 | 35,748 | (6,001) | 29,747 |
| | | 516,015 | (189,137) | 326,878 | 469,407 | (158,532) | 310,875 |
| | | 2,639,099 | (334,579) | 2,304,520 | 2,585,577 | (300,298) | 2,285,279 |
| | | | | | | | |
| | Average amortization rate % p.a. | Consolidated | | | | | |
| | | 9/30/14 | | | 12/31/13 | | |
| | | Cost | Accumulated Amortization | Net | Cost | Accumulated amortization | Net |
| Acquisition of interest - Goodwill | | 2,253,591 | (251,619) | 2,001,972 | 2,253,591 | (251,619) | 2,001,972 |
| Other intangible assets | | | | | | | |
| IT systems | 20 | 202,675 | (123,218) | 79,457 | 157,519 | (100,800) | 56,719 |
| Commercial area use right | 20 | 1,433 | (718) | 715 | 1,203 | (592) | 611 |
| Other intangible assets | 20 | 13,978 | (4,272) | 9,706 | 13,978 | (4,272) | 9,706 |
| System implementation project | 20 | 12,293 | (12,293) | - | 12,293 | (12,293) | - |
| Project development | 33 | 10,267 | (10,169) | 98 | 10,267 | (10,169) | 98 |
| Brands | 3,3 | 251,161 | (31,690) | 219,471 | 250,567 | (24,970) | 225,597 |
| Exclusive agreement with customers - Unimagem | 10 | - | - | - | 9,403 | (4,707) | 4,696 |
| Relationship with hospitals | 5 | 49,297 | (13,689) | 35,608 | 40,488 | (8,185) | 32,303 |
| | | 541,104 | (196,049) | 345,055 | 495,718 | (165,988) | 329,730 |
| | | 2,794,695 | (447,668) | 2,347,027 | 2,749,309 | (417,607) | 2,331,702 |

Notes to Quarterly Information

Changes in cost

| | Company | | | | | 9/30/14 |
|------------------------------------|------------------------------|---|------------------|-------------------|------------------------------|------------------|
| | Changes in the period | | | | | |
| | 12/31/13 | Additions by incorporation (a) | Additions | Write-offs | Transferences (b) | |
| Acquisition of interest - Goodwill | 2,116,170 | 6,914 | - | - | - | 2.123.084 |
| Other intangible assets | | | | | | |
| IT systems | 151,836 | 1,796 | 16,232 | (452) | 28,802 | 198,214 |
| Commercial area use right | 1,203 | - | - | - | 230 | 1,433 |
| Other intangible assets | 12,628 | - | - | - | - | 12,628 |
| System implementation project | 12,293 | - | - | - | - | 12,293 |
| Project development | 10,259 | - | - | - | - | 10,259 |
| Brands | 236,037 | - | - | - | - | 236,037 |
| Exclusive agreement with customers | | - | - | - | - | |
| - Unimagem | 9,403 | - | - | - | - | 9,403 |
| Relationship with hospitals | 35,748 | - | - | - | - | 35,748 |
| | 469,407 | 1,796 | 16,232 | (452) | 29,032 | 516,015 |
| | 2,585,577 | 8,710 | 16,232 | (452) | 29,032 | 2,639,099 |

| | Consolidated | | | | |
|---|------------------------------|------------------|-------------------|------------------------------|------------------|
| | Changes in the period | | | | |
| | 12/31/13 | Additions | Write-offs | Transferences (b) | 9/30/14 |
| Acquisition of interest - Goodwill | 2,253,591 | - | - | - | 2,253,591 |
| Other intangible assets | | | | | |
| IT systems | 157,519 | 16,802 | (497) | 28,851 | 202,675 |
| Commercial area use right | 1,203 | - | - | 230 | 1,433 |
| Other intangible assets | 13,978 | - | - | - | 13,978 |
| System implementation project | 12,293 | - | - | - | 12,293 |
| Project development | 10,267 | - | - | - | 10,267 |
| Brands | 250,567 | - | - | 594 | 251,161 |
| Exclusive agreement with customers - Unimagem | 9,403 | - | - | (9,403) | - |
| Relationship with hospitals | 40,488 | - | - | 8,809 | 49,297 |
| | 495,718 | 16,802 | (497) | 29,081 | 541,104 |
| | 2,749,309 | 16,802 | (497) | 29,081 | 2,794,695 |

(a) Merger of the Company's subsidiaries, as mentioned in Note 3.

(b) Expenses made by the Company classified under Construction in progress for the build-up, implementation and development period of certain establishments, which are transferred to a specific account of fixed or intangible assets when the assets are ready for use.

Notes to Quarterly Information**15. Loans and financing**

| Type | Average rate | Final maturity | Company | | Consolidated | |
|--|---------------------|----------------|-----------------|----------|------------------|-----------|
| | | | 9/30/14 | 12/31/13 | 9/30/14 | 12/31/13 |
| Local currency | | | | | | |
| Banco do Brasil (a) (iii) | 111.0% do CDI | 6/1/2015 | 16,826 | - | 16,826 | 23,884 |
| Banco do Brasil (iii) | 108.0% do CDI | 6/10/2018 | 60,398 | - | 60,398 | - |
| BNDES - FINAME PSI (v) | 6% p.a | 6/15/2024 | 3,475 | - | 3,475 | - |
| Financial lease - Sundry banks - Note 26 (i), (ii) and (iii) | CDI + 2.85% p.a. | 10/26/2015 | 5,430 | 2 | 5,430 | 11,101 |
| | | | 86,128 | 2 | 86,128 | 34,985 |
| Foreign currency | | | | | | |
| Financing of equipment (i), (ii) and (iii) | 7.10% p.a. | 12/1/2016 | 1,641 | - | 1,898 | 2,808 |
| Financial lease - Sundry banks - Note 26 (ii) and (iii) | 6.30% p.a. | 3/23/2016 | 2,798 | 8,429 | 3,485 | 10,033 |
| Credit Agricole Bank (b) (iii) (iv) | 1.32% p.a. | 8/20/2014 | - | - | 73,643 | 70,623 |
| | | | 4,439 | 8,429 | 79,026 | 83,464 |
| Transaction cost - issue of notes (c) | | | - | - | - | (1,412) |
| | | | 90,567 | 8,431 | 165,154 | 118,449 |
| Current liabilities | | | (37,890) | (6,628) | (112,477) | (100,942) |
| Noncurrent liabilities | | | 52,677 | 1,803 | 52,677 | 17,507 |

Guarantors:

- (i) DASA Real Estate Empreendimentos Imobiliários Ltda.
- (ii) Promissory Note of 125% of contractual amount in the Company's name.
- (iii) Diagnósticos da América S.A.
- (iv) Short-term investments with guarantee are securities of public and private entities acquired by subsidiary DASA Finance Corporation.
- (v) Financed asset.

Loan and financing agreements do not have covenants.

- (a) This refers to fundraising for working capital in subsidiaries Sérgio Franco, CDPI and CRMI.
- (b) This refers to loan transactions with subsidiary DASA Finance Corporation, in order to exercise the call option for all notes issued by DASA Finance, maturing in 2018 (8.75% Senior Notes due 2018).
- (c) The transaction cost amounts were appropriated to income on the repurchase date of Notes.

Notes to Quarterly Information

Loans and financing classified as non-current liabilities, according to the contractual maturity dates, will be repaid as follows:

| | <u>In the Company and Consolidated</u> |
|-----------------|--|
| As from 10/2015 | 5,125 |
| 2016 | 18,646 |
| 2017 | 17,568 |
| 2018 | 8,997 |
| 2019 a 2024 | 2,341 |
| | <u>52,677</u> |

The Company granted collaterals to its subsidiaries as follows:

| | | |
|--|------------------|---------------|
| CientificaLab Produtos Lab. e Sistemas Ltda. | Banco Pottencial | 409 |
| DASA Finance Corporation | Banco do Brasil | 57,599 |
| Pro Echo Cardiodata Serviços Médicos Ltda. | General Eletric | 8,988 |
| | Banco Itaú S.A. | 1,099 |
| | | <u>68,095</u> |

16. Debentures (Company and consolidated)

| | <u>9/30/14</u> | <u>12/31/13</u> |
|---------------------------|------------------|------------------|
| Nonconvertible debentures | 1,104,167 | 1,337,500 |
| Compensatory interest | 57,951 | 26,160 |
| | <u>1,162,118</u> | 1,363,660 |
| Transaction cost | (5,373) | (6,934) |
| | <u>1,156,745</u> | 1,356,726 |
| Current | (351,703) | (319,912) |
| Noncurrent | <u>805,042</u> | <u>1,036,814</u> |

Deadline for amortization of the main value of second- and third-issue debentures is as follows:

| | |
|------------|------------------|
| 10/25/2014 | 62,500 |
| 04/29/2015 | 233,333 |
| 10/25/2015 | 62,500 |
| 04/29/2016 | 233,334 |
| 10/25/2016 | 62,500 |
| 10/17/2017 | 225,000 |
| 10/17/2018 | 225,000 |
| | <u>1,104,167</u> |

2nd Issue

In the meeting held on March 16, 2011, the Board of Directors of the Company approved a fund raising by conducting the 2nd issue of simple debentures non-convertible into shares of the Company, for public distribution in the total amount of up to R\$810,000, on a firm guarantee and better efforts of placement basis, under the terms of CVM Ruling No. 476 of January 16, 2009, as amended.

Notes to Quarterly Information

On May 16, 2011, the Company communicated to its shareholders and the market in general that on May 11, 2011, it closed the public offer for distribution with restricted placement efforts, of a single series of simple debentures non-convertible into shares, of the unsecured type. Seventy thousand 70,000 debentures were subscribed for a 5-year term from the date of issue, in the total amount of R\$ 700,000. The debenture remuneration is equivalent to 100% of the accumulated variation of the Inter-financial Deposit (DI) daily average rates, "over extra-group", expressed in percentage per annum and based on 252 working days, as calculated and daily disclosed by the Clearing House for the Custody and Financial Settlement of Securities (CETIP), plus an exponential surcharge of 1.40%. As the issue date was April 29, 2011, the face value of each debenture will be paid in 3 consecutive annual installments, as from the 36th month from the issue date. Payment of remuneration interest is semiannual, occurring on the 1st day of April and October, and the debit in the Company account shall occur one day prior to due date.

3rd Issue

On October 15, 2012, the Board of Directors of the Company approved the third issue by the Company, of up to 25,000 debentures non-convertible into shares of the unsecured type, in a single series, in the total amount of up to R\$250,000, for placement through a public offer with restricted efforts, pursuant to CVM Instruction No. 476 of January 16, 2009, as amended.

On November 1, 2012, the Company communicated to its shareholders and the market in general that on October 31, 2012 it had closed the public offer for distribution, with restricted placement efforts, of the third issue of DASA's simple debentures non-convertible into shares, of the unsecured type, in one single series. Twenty-five thousand (25,000) debentures were subscribed for a 4-year term from the date of issue, in the total amount of R\$ 250,000. The debentures are not subject to monetary adjustment, and the debit balance of each debenture face value will incur an interest equivalent to 100% of the accumulated variation of the Inter-financial Deposit (DI) daily average rates, "over extra-group", expressed in percentage per annum and based on 252 working days, as calculated and daily disclosed by CETIP, plus a surcharge of 0.80% per annum, calculated based on 252 business days, exponentially and cumulatively, on a pro rata temporis basis, per business day elapsed from the Date of Issue or the payment date of the immediately prior remuneration, as the case may be, until the effective payment date.

Interest will be paid semiannually from the Issue Date, the first payment beginning on April 25, 2013 and the last payment to be made on the Maturity Date, without prejudice to payments resulting from early redemption of the Debentures, early repayment of the Debentures and/or prepayment of obligations arising out of the Debentures.

The face value of each Debenture will be repaid in 4 annual and successive installments, in the following order:

- I. Three installments, each in the amount corresponding to 25% of the face value of each Debenture, due on October 25, 2013, October 25, 2014 and October 25, 2015; and
- II. One installment in the amount corresponding to the outstanding balance of the face value of each Debenture, due on October 25, 2016.

The financial settlement of the offer occurred on October 31, 2012 in the amount of R\$250,304, and the net proceeds of the offer were used towards (i) the early redemption of all commercial promissory notes of the third issue of the Company; and (ii) the balance to reinforce the working capital of the Company.

Notes to Quarterly Information

4th Issue

On September 13, 2013, the Company's Board of Directors approved the fourth issue of debentures by the Company, in a single series of up to 45,000 unregistered debentures not convertible into shares totaling up to R\$450,000 for placement through public offering with restrict placement efforts under the terms of CVM Rule No. 476 of January 16, 2009, as amended.

On October 18, 2013, the Company communicated its shareholders and the general market that the public offering with restrict placement efforts of simple, unregistered debentures not convertible into shares, in a single series, of the 4th issue was concluded on October 17, 2013. 45,000 debentures, effective for 5 years from issue date, amounting to R\$450,000 were subscribed. These debentures will not be subject to monetary restatement and, over the debt balance of the nominal value of each debenture, compensatory interest will be levied, corresponding to 100% of accumulated daily average interbank deposits (DI) rate, "over extra-group", expressed in percentage per year, on a 252 business days basis and disclosed by CETIP plus a surtax of 1.15% per year, on a 252 business days basis, computed on an exponential and cumulative manner, pro rata temporis, per business days elapsed since payment day or the date when the prior remuneration is paid, as the case may be, until the effective payment.

Remuneration is to be paid on a half-yearly basis as from issue date, with first payment on April 15, 2014, and last payment on maturity date, not affecting payments made referring to anticipate redemption of debentures, early amortization of debentures and/or early maturity of obligations arising from debentures.

Principal amount will be amortized in two annual installments, in the 48th and 60th month, as from the debentures issue date.

Financial settlement of this offering occurred on October 16, 2013, amounting to R\$450,000, and the net funds from the offering were used to reinforce the working capital and refinancing of debts.

The debentures have clauses determining the maximum indebtedness and leverage levels, based on the consolidated quarterly financial information.

At the end of the period, the Company was in compliance with the contractual conditions, as follows:

| Indicator | Contractual terms (a) | Condition at 9/30/14 | Condition at 12/31/13 |
|---|-----------------------|----------------------|-----------------------|
| EBITDA - Last 12 months (b) | | 356,162 | 443,594 |
| Financial income - Last 12 months (b) | | 74,758 | 86,584 |
| Net debt | | 729,748 | 866,209 |
| 1- Net debt / <i>EBITDA</i> - maximum index | | | |
| 2 ^a Issuance | 2.50 | 1.56 | 1.95 |
| 3 ^a Issuance | 3.00 | 1.56 | 1.95 |
| 4 ^a Issuance | 3.00 | 1.56 | 1.95 |
| 2- <i>EBITDA</i> / Financial income - minimum index | | | |
| 2 ^a Issuance | 2.00 | 4.94 | 5.12 |
| 3 ^a Issuance | 2.00 | 4.94 | 5.12 |
| 4 ^a Issuance | 2.00 | 4.94 | 5.12 |

(a) The Company will be deemed to be in non-compliance with this covenant if it exceeds such ratios for two consecutive quarters

(b) The information and EBITDA are not part of the scope of the auditor's review work.

Notes to Quarterly Information**17. Taxes in installments**

| | Completion of payments | Company | | Consolidated | |
|------------------------|------------------------|----------------|----------|----------------|----------|
| | | 9/30/14 | 12/31/13 | 9/30/14 | 12/31/13 |
| REFIS IV - Federal (a) | 2020 | 9,751 | 9,678 | 17,454 | 18,853 |
| ICMS - RJ (a) and (b) | | 1,787 | - | 1,787 | 5,102 |
| ISS - CERPE | | - | - | 2,704 | 2,848 |
| ISS - CRMI | | 410 | - | 410 | - |
| Other | | 1,079 | 860 | 1,350 | 2,382 |
| | | 13,027 | 10,538 | 23,705 | 29,185 |
| Current | | (1,354) | (1,108) | (1,861) | (4,293) |
| Noncurrent | | 11,673 | 9,430 | 21,844 | 24,892 |

(a) The variations occurred in the nine-month period ended September 30, 2014 are related to interest and payments during the period updates.

The details of these tax installments are presented in Note 19 (b) of the financial statements for the year ended December 31, 2013.

(b) Installment ICMS - RJ

On February 25, 2014, an order from the State Department for Civil Affairs was published in the Rio de Janeiro State Official Gazette (DOERJ) which formalized the deferral of administrative proceeding E14-515.135/2012 corresponding to one (1) of two (2) requested offset of VAT credit taxes presented by CRMI. Accordingly, the VAT tax credits has already been recorded through both the write-off of State VAT (ICMS) tax debits stated in that request, as well as the respective court ordered debt used which totaled R\$ 2,945. Furthermore, the portion of negative goodwill relating to that court ordered debt was also recognized under Financial expenses at the amount of R\$960. Payment of 5% of the tax amnesty amount, not offsettable by the court ordered debt was made on June 3, 2014, on notice from the PGE (State Attorney General).

18. Accounts payable for acquisitions of subsidiaries

Accounts payable for acquisition of subsidiaries relate to the amounts due to their former owners upon the acquisition of shares or quotas representing the paid-in capital of these companies. Debts are restated in accordance with contractual clauses:

| | Restatement | Maturity | Company | | Consolidated | |
|---|-----------------|--------------------|----------------|----------|----------------|----------|
| | | | 9/30/14 | 12/31/13 | 9/30/14 | 12/31/13 |
| Not guaranteed by marketable securities | IPCA-IGPM-Selic | 5/2016 | 8,399 | 10,566 | 8,399 | 10,566 |
| Guaranteed by marketable securities | (a) | 11/2016 and 4/2017 | 26,954 | 26,184 | 37,330 | 37,793 |
| | | | 35,353 | 36,750 | 45,729 | 48,359 |
| Current | | | (1,758) | (1,689) | (1,758) | (1,689) |
| Noncurrent | | | 33,595 | 35,061 | 43,971 | 46,670 |

(a) Restated at the average rate of 101.27% of CDI (101.25% of CDI at December 31, 2013) for fixed-income funds, and 102.76% of CDI (100.01% of CDI at December 31, 2013) for CDB/committed transactions, which are managed by financial entities, as shown in Note 8.

Notes to Quarterly Information

The installments classified as non-current liabilities have the following payment schedule:

| Aging list | Company | Consolidated |
|-----------------|---------|--------------|
| As from 07/2015 | 13,721 | 13,721 |
| 2016 | 19,758 | 25,610 |
| 2017 a 2020 | 116 | 4,640 |
| Total | 33,595 | 43,971 |

19. Provisions for tax, social security, labor and civil proceedings

| | Company | | | |
|-----------------------------------|--------------|------------------|-----------|------------------|
| | 9/30/14 | | 12/31/13 | |
| | Provision | Judicial deposit | Provision | Judicial deposit |
| ICMS on import (a) | 5,644 | 1,626 | 4,942 | 54,696 |
| Labor and civil contingencies (b) | 20,230 | 13,716 | 6,496 | 9,677 |
| Tax contingencies (c) | 33,170 | 33,299 | 26,056 | 26,322 |
| | 59,044 | 48,641 | 37,494 | 90,695 |
| | Consolidated | | | |
| | 9/30/14 | | 12/31/13 | |
| | Provision | Judicial deposit | Provision | Judicial deposit |
| ICMS on import (a) | 5,644 | 1,626 | 4,942 | 54,696 |
| Labor and civil contingencies (b) | 20,733 | 14,926 | 6,997 | 13,121 |
| Tax contingencies (c) | 34,844 | 33,954 | 28,506 | 27,723 |
| | 61,221 | 50,506 | 40,445 | 95,540 |

(a) ICMS on import

Following the opinion of its legal advisors, the Company has not paid ICMS on the import of inputs and equipment for use in the rendering of its services since February 2000, as there are ongoing discussions as to whether the Company is an ICMS taxpayer for these transactions. For ICMS payables on goods and equipment imported up to the publication of Constitutional amendment 33 on December 11, 2001, the external legal advisors understand that the likelihood of losses is remote; as regarding to ICMS payables generated between the Constitutional Amendment 33 date and the issuance of the supplementary Law No. 114, on December 16, 2002, the likelihood of loss was classified as possible. For import of equipment under the lease modality, the likelihood of loss was also deemed as possible. Finally, after enactment of the supplementary Law No. 114 on December 16, 2002, the external legal advisors understand that the likelihood of loss is probable.

Of the amount of R\$ 54,696, which represented the restated balance of December 31, 2013 of the judicial deposits amount, R\$ 53,732 corresponded to the restated amount of deposit in December 2011 (to the original deposit amount R\$46,849) referring to ICMS amounts charged on direct import transactions of inputs and equipment cleared in the state of São Paulo, for which no process was served, pledging the voluntary payment of taxes, without fines and with decreased interest, maintaining the criteria for computation of provision amounts. Because the Company had settled after adhering to PEP of ICMS/SP in 2013, which covered all tax debts guaranteed by this deposit, the determination of the judicial deposit amount was required. On February 25, 2014, the Company, completed the calculation of ICMS on direct imports, deposited in court in December 2011, based on MS records No. 0046827-27.2011.8.26.0053.

(b) Provision for labor and civil contingencies

At September 30, 2014, the Company was a party to administrative and legal suits, including 1,551 labor claims (1,306 at December 31, 2013) and to 1,222 administrative and legal civil claims (1,122 at December 31, 2013). Provisions recorded in the Company's and in the consolidated financial statements amounting to R\$ 20,230 (R\$ 6,496 at December 31, 2013) and to R\$ 20,733 (R\$ 6,997 at December 31, 2013), respectively, are based on the history of losses. Moreover, at September 30, 2014, the Company recorded the consolidated amount of R\$ 88,942 (R\$ 109,260 at December 31, 2013) in connection with proceedings assessed as possible losses by its legal advisors, including R\$18,649 referring to civil claims and R\$ 66,628 referring to labor claims, for which no provision has been recognized.

Notes to Quarterly Information

At September 30, 2014, the Company is a party to 1,552 labor claims (1,306 at December 31, 2013) and to 1,222 administrative and legal civil claims (1,122 at December 31, 2013). Provisions recorded in the Company's and in the consolidated financial statements amounting to R\$ 20,230 (R\$ 6,496 at December 31, 2013) and to R\$ 20,733 (R\$ 6,997 at December 31, 2013), are based on the history of probable, possible and remote losses. Moreover, at September 30, 2014, the Company recorded the consolidated amount of R\$ 88,942 (R\$ 109,260 at December 31, 2013) in connection with proceedings assessed as possible losses by its legal advisors, including R\$18,649 referring to civil claims and R\$ 94,760 referring to labor claims, for which no provision has been recognized, in accordance with the applicable accounting standard, considering the history of losses on cases assessed as possible risks.

As for labor claims classified as possible loss, we should mention the Public Civil Action at the Rio de Janeiro Labor Court, to which the Company and Laboratórios Médicos Dr. Sérgio Franco Ltda., an entity merged into the Company on July 1, 2014, are a party. In general, questioning the legality of the arrangements with health companies specialized in diagnostic support services by imaging, which required hiring doctors bound to said healthcare companies under the Consolidation of Labor Laws (CLT) and a collective indemnification for pain and suffering of approximately R\$ 20,000 on September 10, 2012. On June 26, 2014, the Company released a new Material Fact disclosing that a decision was handed down entirely favorable to the Company in the lower court. The Federal Department of Justice has appealed against the decision and awaits trial.

(c) Provision for tax contingencies

The provisions for tax contingencies in the amount of R\$ 33,170 (R\$ 26,056 at December 31, 2013) in Company, and R\$ 34,844 (R\$ 28,506 at December 31, 2013) in consolidated, relate to: (i) questionings for increases in rates; (ii) calculation base; and (iii) unconstitutionality of collection. Such questionings refer basically to PIS, COFINS, INSS and FGTS contributions. At September 30, 2014, the Company recorded a consolidated amount of R\$ 245,600 (R\$ 265,768 at December 31, 2013), related to claims classified by its legal advisors as possible loss, for which there were no provisions, according to the accounting rule applicable for those circumstances, and substantially R\$ 133,000 was related to ICMS claims (Taxes) over import of leasing equipment and direct import of inputs and equipment performed between the EC33 (issued in December 2001) and the Supplementary Law No. 114 (issued in December 2002), and R\$ 112,600 related to other PIS, COFINS, IRPJ and ISS tax claims.

Changes in provisions for contingencies

| | Company | | | | |
|---|------------------------|--------------------------------------|-----------------------------------|-------------------------|------------------------|
| | 12/31/13 | Change for the period | | | 9/30/14 |
| | Closing balance | Addition by incorporation (a) | Additions to provision (b) | Use and reversal | Restatement (b) |
| ICMS on import | 4,942 | - | - | (171) | 873 |
| Provision for labor and civil contingencies | 6,496 | - | 19,905 | (6,171) | - |
| Provision for tax contingencies | 26,056 | 776 | - | (415) | 6,753 |
| | 37,494 | 776 | 19,905 | (6,757) | 7,626 |
| | | | | | 59,044 |

| | Consolidated | | | | |
|---|------------------------|-----------------------------------|-------------------------|--------------------|------------------------|
| | 12/31/13 | Change for the period | | | 9/30/14 |
| | Closing balance | Additions to provision (b) | Use and reversal | Restatement | Closing balance |
| ICMS on import | 4,942 | - | (171) | 873 | 5,644 |
| Provision for labor and civil contingencies | 6,997 | 19,907 | (6,171) | - | 20,733 |
| Provision for tax contingencies | 28,506 | - | (415) | 6,753 | 34,844 |
| | 40,445 | 19,907 | (6,757) | 7,626 | 61,221 |

(a) Additional provision at the parent Company refers to the merger of subsidiaries on July 1, 2014, as mentioned in Note 3

(b) Additional provision for labor and civil contingencies refers to new proceedings filed against the Company for the period according to the history of losses.

Notes to Quarterly Information**20. Equity**a) Share-based payment*Changes in the period of options granted in May 2011:*

| | <u>Common shares</u> | <u>R\$</u> |
|---------------------------------|----------------------|------------|
| Balance at December 31, 2013 | 92,754 | 1,350 |
| Additions | 13,822 | 301 |
| Equity-settled transactions (a) | 106,576 | (1,651) |
| Balance at September 30, 2014 | <u>-</u> | <u>-</u> |

(a) The Board of Directors approved at a meeting held on May 27, 2014, the transfer of 106,576 treasury shares in private transactions to beneficiaries and holders of stock option related to the First Program plan. These treasury shares were granted and exercised in accordance with their terms and conditions, in compliance with the provisions of section 5 of the First Program, and as permitted by Article 3, section II of CVM Ruling No. 390, dated July 8, 2003. Considering the amount of R\$15.49 per share at the close of business on BM&FBovespa on May 27, 2014, the amount of R\$1,651 was recorded as a settlement of the options granted in May 2011.

Share-based payment transactions - June 2012

| | <u>Common shares</u> | <u>R\$</u> |
|-------------------------------|----------------------|--------------|
| Balance at December 31, 2013 | 107,592 | 1,567 |
| Cancelled | (13,113) | (184) |
| Additions | 51,378 | 373 |
| Balance at September 30, 2014 | <u>145,857</u> | <u>1,756</u> |

Details of the Stock Option Plan are shown in Note 22 (e) of the financial statements for year ended December 31, 2013.

b) Treasury shares

| <u>Description of operation</u> | <u>Number of shares</u> | <u>Amount</u> | <u>Average price per share</u> |
|---------------------------------|-------------------------|----------------|--------------------------------|
| Balance at December 31, 2013 | 1,159,035 | 18,617 | 16.06 |
| Transfer (a) | <u>(106,576)</u> | <u>(1,712)</u> | 16.06 |
| Balance at September 30, 2014 | <u>1,052,459</u> | <u>16,905</u> | 16.06 |

(a) Transfer refers to the settlement of options granted in the amount of R\$ 1,651, as disclosed in item (a) of this note, plus R\$ 61 adjustment related to the average historical value per share of treasury shares, registered against Special Goodwill Reserve on Merger account.

Notes to Quarterly Informationc) Earnings per share*Basic*

Basic earnings per share are calculated by dividing the income attributable to the Company's shareholders by the weighted average number of common shares issued over the period, less common shares purchased by the Company and held as treasury shares.

| | <u>1/1/14 a 9/30/14</u> | <u>1/1/13 a 9/30/13</u> |
|---|-------------------------|-------------------------|
| Income attributable to Company shareholders | 103,837 | 94,591 |
| Weighted average number of common shares issued | 311,803 | 311,803 |
| Weighted average of treasury shares | <u>(1,052)</u> | <u>(1,159)</u> |
| Weighted average of outstanding common shares | 310,751 | 310,644 |
| Basic earnings per share - R\$ | 0.33415 | 0.30450 |

Diluted

Diluted earnings per share are calculated by adjusting the weighted average number of outstanding common shares considering the conversion of all potential common shares that would cause dilution. The Company has only one category of dilutive potential common shares: stock options, disclosed in item (a) of this Note.

| | <u>1/1/14 a 9/30/14</u> | <u>1/1/13 a 9/30/13</u> |
|---|-------------------------|-------------------------|
| Income attributable to Company shareholders | 103,837 | 94,591 |
| Weighted average of outstanding common shares | 310,751 | 310,644 |
| Adjustment for acquisition of shares | <u>193</u> | <u>319</u> |
| Weighted average number of common shares for diluted earnings per share | 310,944 | 310,963 |
| Diluted earnings per share - R\$ | 0.33394 | 0.30419 |

d) Capital

In a session held on July 16, 2014, the Brazilian Antitrust Agency ("CADE") approved the acquisition of Company ordinary shares by Cromossomo Participações II S/A. As a result, Edson de Godoy Bueno and Dulce Pugliese de Godoy Bueno (indirect holders of all of the shares in Cromossomo) are now direct and indirect controllers of more than 70% of the Company's capital, pursuant to Antitrust Review Process No. 08700.002372/2014-07. Approval by CADE was subject to compliance with an Antitrust Control Agreement ("ACC"), current mechanism introduced by the antitrust law (Law No.12529/11) to replace the Performance Commitment Instrument effective under Law No. 8884/94.

ACC requires Cromossomo's shareholders to formally adhere to the obligations defined in the Performance Commitment Instrument executed by and between the Company and CADE, pursuant to Antitrust Review Process No. 08012.010038/2010-4, which reviewed the Company's association with MD1 Diagnósticos S.A. and other entities, as described in the Notice of Material Event published by the Company on December 4, 2013.

Notes to Quarterly Information

21. Income and social contribution taxes

The company records monthly provisions for income and social contribution taxes on an accrual basis.

Taxes are calculated by taxable income, except for subsidiaries, Multi-Imagem Petrópolis Dasa Centro Oeste, Dasa Nordeste, Dasa Sudoeste and Dasa Property, in which it adopted the presumed profit system.

Reconciliation of the expense calculated by applying combined rates for income and social contribution tax expenses charged to income is shown as follows:

| | Company | | Consolidated | |
|--|-----------------|-----------------|-----------------|-----------------|
| | 9/30/14 | 9/30/13 | 9/30/14 | 9/30/13 |
| Income before income and social contribution taxes | 131,690 34% | 125,031 34% | 154,223 34% | 148,326 34% |
| Income and social contribution taxes: at combined tax rate | (44,775) | (42,511) | (52,436) | (50,431) |
| Permanent exclusions (additions) | | | | |
| Equity pickup | 20,694 | 14,732 | - | - |
| Interest in paid-in capital | (2,655) | (1,274) | - | - |
| Nondeductible expenses | (1,198) | (1,153) | (553) | (1,343) |
| Other adjustments | | | | |
| Income of subsidiary abroad | - | - | 1,524 | (4,211) |
| Taxable profit computed as a percentage of gross sales (Deemed profit taxation) | - | - | 277 | 1,224 |
| Goodwill on downstream merger | - | - | 1,146 | 1,146 |
| Other | 81 | (234) | (14) | 13 |
| | (27,853) | (30,440) | (50,056) | (53,602) |
| Current income and social contribution Taxes | (6,610) | - | (29,560) | (26,930) |
| Deferred taxes | (21,243) | (30,440) | (20,496) | (26,672) |
| Total | (27,853) | (30,440) | (50,056) | (53,602) |
| Effective rate | 21% | 24% | 32% | 36% |

The 34% combined tax rate used for 2014 and 2013 calculations applies to taxable profit for legal entities in Brazil as required by the tax laws of this jurisdiction.

Deferred taxes on tax losses and temporary provisions

Income and social contribution taxes are stated so as to reflect future tax effects attributable to temporary differences between the assets and liabilities tax bases and their respective book values.

In accordance with CPC 32, based on the expectation of generating future taxable profit backed by a technical study approved by our management, the Company recognizes tax credits and debits on deductible temporary differences and accumulated tax losses and negative bases for social contribution, which are not subject to limitation and may be used to offset up to 30% of annual taxable profit. The book value for deferred tax assets and liabilities is reviewed quarterly and projections are reviewed annually.

Notes to Quarterly Information

The composition of the balances of deferred income and social contribution taxes assets and liabilities are shown below:

| | Balance sheet | | Income (loss) |
|---|----------------------|-----------------|----------------------|
| | Company | | Company |
| | 9/30/14 | 12/31/13 | 9/30/14 |
| Income tax losses and negative basis for social contribution | 194,672 | 169,286 | 25,386 |
| Allowance for doubtful accounts and disallowances | 18,951 | 15,748 | 3,203 |
| Provision for specialized medical services | 13,849 | 9,820 | 4,029 |
| Sundry provisions | 11,102 | 5,701 | 5,401 |
| Provision for obsolescence | 365 | - | 365 |
| Provision for contingencies | 15,889 | 7,767 | 8,122 |
| Other | 1,378 | 622 | 756 |
| Goodwill amortization | (260,882) | (194,206) | (66,676) |
| Intangibles identified in acquisitions | (81,516) | (84,218) | 2,702 |
| Review of property and equipment useful lives | (8,443) | (11,870) | 3,427 |
| Others | (6,721) | (861) | (5,860) |
| Deferred income and social contribution taxes - Assets / (Liabilities) | (101,356) | (82,211) | |
| Revenue (expenses) from income and social contribution - deferred | | | (19,145) |
| Reflected in the balance sheet as follows: | | | |
| Deferred tax liabilities | (101,356) | (82,211) | |
| Deferred income and social contribution taxes - Assets / (Liabilities) | (101,356) | (82,211) | |
| Reconciliation of tax assets (liabilities) - deferred | | | |
| | 9/30/14 | | |
| Balance at December 31, 2013 | (82,211) | | |
| Income / (expenses) from taxes recognized in income (loss) | (21,243) | | |
| Income (expenses) revenue from development | 2,098 | | |
| Balance at September 30, 2014 | (101,356) | | |

Notes to Quarterly Information

| | Balance sheet | | Income (loss) |
|--|----------------------|-----------------|----------------------|
| | Consolidated | | Consolidated |
| | 9/30/14 | 12/31/13 | 9/30/14 |
| Income tax losses and negative basis for social contribution | 238,787 | 208,656 | 30,131 |
| Allowance for doubtful accounts and disallowances | 24,414 | 22,874 | 1,540 |
| Goodwill amortization | 12,634 | 18,850 | (6,216) |
| Provision for specialized medical services | 14,828 | 12,252 | 2,576 |
| Sundry provisions | 11,182 | 5,701 | 5,481 |
| Provision (-) Obsolete items | 365 | - | 365 |
| AVP - Accounts receivable long term | 323 | - | 323 |
| Provision for contingencies | 16,603 | 8,634 | 7,969 |
| Other | 1,378 | 773 | 605 |
| Goodwill amortization | (261,492) | (195,385) | (66,107) |
| Intangibles identified in acquisitions | (86,860) | (89,728) | 2,868 |
| Review of useful life of property and equipment | (9,292) | (9,144) | (148) |
| Other | (7,575) | (7,692) | 117 |
| Deferred income and social contribution taxes - Assets/ (Liabilities) | (44,705) | (24,209) | |
| Revenue (expenses) from income and social contribution taxes - deferred | | | (20,496) |
| Reflected in the balance sheet as follows: | | | |
| Deferred tax assets | 56,651 | 58,002 | |
| Deferred tax liabilities | (101,356) | (82,211) | |
| Deferred income and social contribution taxes - Assets/ (Liabilities) | (44,705) | (24,209) | |
| Reconciliation of deferred tax assets (liabilities) | 9/30/14 | | |
| Balance at December 31, 2013 | (24,209) | | |
| Income / (expenses) from taxes recognized in income (loss) | (20,496) | | |
| Other | | | |
| Balance at September 30, 2014 | (44,705) | | |

Company management considers that the deferred income and social contribution tax asset balances from temporary expenses will be realized to the proportion of the contingencies and realization of events triggering such provisions for losses.

The Company did not identify evidence that deferred taxes will not be recoverable over the nine-month period ended September 30, 2014.

Notes to Quarterly Information

22. Cost of services provided

| | Company | | Consolidated | |
|-------------------------------|------------------|----------------|------------------|------------------|
| | 9/30/14 | 9/30/13 | 9/30/14 | 9/30/13 |
| Personnel | 307,441 | 252,868 | 401,274 | 355,662 |
| Material | 277,384 | 214,603 | 370,788 | 327,589 |
| Services and utilities | 441,853 | 378,103 | 533,395 | 496,074 |
| Depreciation and amortization | 65,499 | 57,552 | 81,017 | 75,024 |
| General expenses | 20,707 | 13,284 | 25,226 | 19,115 |
| | 1,112,884 | 916,410 | 1,411,700 | 1,273,464 |

23. General and Administrative Expenses by nature

| | Company | | Consolidated | |
|--|----------------|----------------|----------------|----------------|
| | 9/30/14 | 9/30/13 | 9/30/14 | 9/30/13 |
| Personnel expenses | 142,625 | 125,829 | 181,360 | 168,255 |
| Provision for profit sharing and bonus | 29,700 | 19,557 | 29,700 | 21,422 |
| Services and utilities | 66,172 | 46,372 | 88,715 | 72,036 |
| Advertising and publicity | 9,139 | 7,183 | 9,908 | 8,454 |
| Freight costs | 29,079 | 25,476 | 33,617 | 29,249 |
| Depreciation and amortization | 44,760 | 37,685 | 46,164 | 40,800 |
| Taxes and charges | 863 | 2,965 | 1,618 | 5,011 |
| Sundry provisions (a) | 23,372 | 9,970 | 24,283 | 11,136 |
| General expenses | 18,570 | 15,276 | 22,570 | 24,736 |
| | 364,280 | 290,313 | 437,935 | 381,099 |

(a) Additional provision for labor and civil contingencies as disclosed in Note 19.

24. Financial instruments

The Company is generally exposed to the following operating risks that may affect its strategic and financial objectives to a greater or lesser extent:

- Market risk
- Liquidity risk
- Credit risk
- Operating risk

The Company manages the risks to which it is exposed by defining conservative strategies to ensure liquidity, profitability, and security, using objective criteria for risk diversification. This note reports the Company's exposure to each of the above risks, and its objectives, policies and processes for risk measurement and management and for capital management.

Risk management structure

In alignment with current regulations and with the Company's corporate policies, the system is based on the integrated management of each of the business processes and on adjusting risk level to strategic objectives. The Company's corporate governance structure involves an extensive risk management process for identifying, treating, and monitoring these risks that extends from senior management, and institutional committees such as the auditing committee, which is responsible, among other duties, for overseeing the integrity and effectiveness of internal controls and risk management through to all the Company's different areas.

Notes to Quarterly Information

The Company's internal control environment has been designed to support the nature, risk, and complexity of its operations. It is based on formalized policies and procedures that are disseminated throughout the organization, as well as dedicated business areas and specific tools for risk monitoring.

Management of all risks inherent to the Company's activities on an integrated basis is addressed within a process supported by the structures of Internal Controls and Compliance (in relation to internal policies, rules, and regulations) that ensures continuous improvement for risk management models and minimizes any omission that could jeopardize correct risk identification and assessment. Based on identification, assessment and monitoring of the principal risks, the Company draws up specific action plans to ensure that improvements are implemented.

To build the right control environment for the scale of its business, the Company invests to strengthen internal communication and disseminate the risk management concept among employees. Corporate risk management is supported by statistical tools with liability adequacy testing, stress testing, capital sufficiency indicators and others. In addition to these tools, the Company adds the qualitative side of risk management, with results from self-assessment, quality evaluations, and tests conducted by internal auditing to evaluate the effectiveness and efficiency of internal controls, as well as quality performance in fulfilling duties and responsibilities.

Historically, the financial instruments used by the Company have shown adequate results for risk mitigation. Additionally, we avoid transactions involving exotic or speculative derivatives.

Market risks

These are risks related to assets and liabilities with cash flows or present values that are exposed to:

- a) *Exchange-rate risk*: Risk of loss or gain depending on fluctuations in prices of foreign currencies. The main tool to control exchange-rate related risk is the daily treasury position, which is based on reports provided by the BM&FBovespa and other sources (e.g. the Central Bank) for the control of exchange-rate variations involved in our operations.
- b) *Market risk - interest*: Risk of fluctuating interest rates leading to increased expenses or decreased income. Fixed interest rates maintained to maturity allow certainty for cash flows. Floating interest rates pose volatility for future interest charges. The main tool for control of risk related to interest rates is the daily treasury position, which is based on reports provided by the BM&FBovespa to control interest rates involved in our transactions.

Our principal market risks arise from possible fluctuations in interest rates and exchange rates. As a result, the Company and its subsidiaries seek hedging for liquidity risk through financial instruments such as marketable securities, funding in the form of working capital loans, and funding through the issue of debentures, all on an arms' length basis, as well as USD-CDI index swaps. The Company's market risk management practices are based on the operating strategies and internal controls established in its Internal Policy for Risk Management of Financial Assets ("Policy") in order to ensure liquidity, profitability, and security of financial instruments exposed to risk. These practices consist of periodically monitoring its contractual conditions in comparison with current market conditions.

Every financial transaction is submitted to the Executive Committee and subsequent validation by the board of directors and / or their auxiliary advisory committees. In the cases of exchange rate and interest-rate exposure, guidelines are set by the board of directors and operated by the Treasury department, since they depend of variable components of the economic scenario. Treasury forwards a monthly report to the Executive Committee showing the Company's current exposure to market risks and using reports, documents and contracts checks for compliance with the policy.

Notes to Quarterly Information

In addition to the above, for market risks to which the Company is exposed, Treasury is mandated to run monthly stress tests assuming 25% and 50% variations in relation to original parameters in order to assess the elasticity of these positions when subjected to major variations of the rates involved in these transactions, and their impact on income and cash positions of the Company.

Liquidity risk

Liquidity risk is the risk of an unforeseeable event or an error in calculating liquidity requirements that will impact the Company's investment decisions or day-to-day business.

We manage liquidity risk by maintaining adequate reserves, bank credit facilities, and credit lines from funding as deemed appropriate, continuously monitoring expected and actual cash flows and the combination of maturity profiles of financial assets and liabilities, following these guidelines:

- a) Short-term cash management - liquid assets and credit facilities to cover immediate needs. Periodicity: Daily. Periodicity: D+1 (working days);
- b) Long-term cash management - Continuous process to ensure long-term funds, through analysis of the cash budget on a monthly basis, updating assumptions made in the budget in accordance with business needs, and comparing actual *versus* estimated performance. Periodicity: Monthly. Term: 5th working day of the month following the report's base date;
- c) Maintenance of minimum cash - Refers to cash balances the Company may replenish in a very short period of time to meet any urgent requirements. In addition, it uses the criterion that cash holdings must be sufficient to cover the five worst daily cash flows in a month, not including receivables;
- d) Exposure limits and risk mitigation - the treasury department keeps short-term facilities for immediate liquidity and working capital lines, so that volume is sufficient to ensure at least the amount equal to that of the highest cash outflow over five consecutive days in the last 12 months.

For medium and long term credit lines, the Treasury department maintains credit lines compatible with the Company's strategic planning, for the purpose of ensuring the availability of resources to meet the estimated cash flow.

The table below details the aging list of the consolidated financial liabilities at September 30, 2014:

| Consolidated Transaction | Maturity | | | | Total |
|--|----------------|---------------|----------------|-----------------|------------------|
| | 2014 | 2015 | 2016 a 2017 | 2018 onwards | |
| Trade accounts payable | 87,530 | - | - | - | 87,530 |
| Loans and financing | 112,477 | 5,125 | 36,215 | 11,337 | 165,154 |
| Debentures | 351,703 | 61,980 | 518,683 | 224,379 | 1,156,745 |
| Taxes in installments | 1,861 | 2,616 | 3,404 | 15,824 | 23,705 |
| Payables for acquisition of subsidiaries | 1,758 | 13,721 | 30,250 | - | 45,729 |
| | 555,329 | 83,442 | 588,552 | 251,540 | 1,478,863 |

Credit risk

Refers to the risk of loss resulting from inability of the counterparty to meet its contractual obligations and make payments to the Company. The principal means of mitigating this risk is through the credit analysis process. Measurement of credit risk over time will be based mainly on the determination of the allowance for doubtful accounts.

Notes to Quarterly Information

The Company and its subsidiaries are subordinated to the credit policy set by its management and their purpose is to minimize any problems deriving from default due to disallowances under plans. The Company also set up an allowance for doubtful accounts due to disallowances, default and returned checks in the Company amounting to R\$55,738 (R\$46,318 at December 31, 2013) representing 8.66% (10.62% at December 31, 2013) from the balance of outstanding receivables in order to cover credit risk, and in Consolidated R\$71,955 (R\$67,486 at December 31, 2013) representing 9.53% (10.56% at December 31, 2013) from the balance outstanding receivables in order to cover the credit risk.

At September 30, 2014, the maximum exposure in consolidated was R\$1,271,319 (R\$1,175,059 at December 31, 2013) referring to cash and cash equivalents and receivables.

Operating risk

Operating risk is the risk of direct or indirect loss arising from a variety of causes associated with our personnel, technology and infrastructure processes, as well as external factors, other than credit, market and liquidity risks. It includes risks such as those arising from legal and regulatory requirements and generally accepted standards of corporate conduct. Operating risks arise from all our operations.

The objective of the Company is to manage operating risk to prevent the occurrence of financial losses or damage to its reputation while ensuring cost effectiveness and avoiding control procedures that hamper initiative and creativity.

The primary responsibility for developing and implementing controls to cover operating risk is attributed to senior management. The latter is supported by development of overall standards for operating risk management in the following areas:

- requirements for appropriate segregation of duties, including independent authorization of transactions;
- requirements for reconciliation and monitoring transactions;
- compliance with legal and regulatory requirements
- documentation of controls and procedures;
- requirements for periodic assessment of operating risks faced, and adequacy of controls and procedures to treat the identified risks;
- requirements for reporting transaction losses and proposed corrective measures;
- developing contingency plans;
- professional training and development;
- ethical and business standards;
- risk mitigation, including insurance, when effective

Compliance with the Company's rules is supported by a continuous quality assessment process and a program for periodical analysis of the Internal Auditing responsibilities. The results of the Internal Auditing analyses are discussed with the management of the related business unit, and reports are sent to the Auditing Committee and to the Company management.

Notes to Quarterly Information*Capital management*

The Company monitors the financial leverage to maintain an appropriate capital structure for the operation and to reduce the indebtedness cost. The leverage ratio used corresponds to net debt divided by total equity.

The consolidated levels of financial leverage ratios at September 30, 2014 and December 31, 2013 are broken down as follows:

| | <u>9/30/14</u> | <u>12/31/13</u> |
|--|------------------|-----------------|
| Loans and financing (a) | 165,154 | 118,449 |
| Debentures (a) | 1,156,745 | 1,356,726 |
| Derivative financial instruments | | (107) |
| Total gross debt | 1,321,899 | 1,475,068 |
| Cash and cash equivalents and marketable securities – current assets | (592,152) | (608,861) |
| Net debt | 729,747 | 866,207 |
| Equity | 2,813,216 | 2,708,810 |
| Contents | 0.25940 | 0.31977 |

(a) Amounts are reported net of transaction costs

The Company may alter its capital structure depending on economic-financial, strategic or operational conditions, in order to improve debt management. At the same time, it aims to improve return on invested capital (ROIC) through working capital management and an efficient investment program.

The Company is subject to maximum indebtedness levels according to the terms presented in Note 16.

Financial instrument by category

The table below shows the Company's financial instruments by category. Fair values of financial instruments shown do not vary significantly from the balances shown in the Company and Consolidated statements of financial position.

| Description | Company | | | | | |
|--|---|--------------------------|-------------------|---|--------------------------|-------------------|
| | <u>9/30/14</u> | | | <u>12/31/13</u> | | |
| | Fair value through profit or loss | Loans and receivables | Amortized cost | Fair value through profit or loss | Loans and receivables | Amortized cost |
| Cash and cash equivalents and Marketable securities | 507,975 | - | - | 512,755 | - | - |
| Judicial deposits | 48,641 | - | - | 90,695 | - | - |
| Trade accounts receivable | - | 588,202 | - | - | 390,155 | - |
| Derivatives | - | - | - | 107 | - | - |
| Assets | 556,616 | 588,202 | - | 603,557 | 390,155 | - |
| Trade accounts payable | - | - | 79,226 | - | - | 45,804 |
| Loans and financing | - | - | 90,567 | - | - | 8,431 |
| Debentures | - | - | 1,156,745 | - | - | 1,356,726 |
| Derivatives | - | - | - | - | - | - |
| Taxes in installments | - | - | 13,027 | - | - | 10,538 |
| Payables for acquisition of subsidiaries | - | - | 35,353 | - | - | 36,750 |
| Liabilities | - | - | 1,374,918 | - | - | 1,458,249 |

Notes to Quarterly Information

| Description | Consolidated | | | | | |
|--|---|--------------------------|-------------------|---|--------------------------|-------------------|
| | 9/30/14 | | | 12/31/13 | | |
| | Fair value through profit or loss | Loans and receivables | Amortized cost | Fair value through profit or loss | Loans and receivables | Amortized cost |
| Cash and cash equivalents and Marketable securities | 629,482 | - | - | 646,654 | - | - |
| Judicial deposits | 50,506 | - | - | 95,540 | - | - |
| Trade accounts receivable | - | 681,809 | - | - | 572.202 | - |
| Derivatives | - | - | - | 107 | - | - |
| Assets | 679,988 | 681,809 | - | 742,301 | 572.202 | - |
| Trade accounts payable | - | - | 87,530 | - | - | 65,479 |
| Loans and financing | - | - | 165,154 | - | - | 118,449 |
| Debentures | - | - | 1,156,745 | - | - | 1,356,726 |
| Taxes in installments | - | - | 23,705 | - | - | 29,185 |
| Payables for acquisition of subsidiaries | - | - | 45,729 | - | - | 48,359 |
| Liabilities | - | - | 1,478,863 | - | - | 1,618,198 |

Fair value hierarchy

The Company holds only financial instruments qualified at level 2, corresponding to marketable securities in the consolidated amounts of R\$612,651 at September 30, 2014 (R\$625,786 at December 31, 2013).

The different levels are defined as follows:

- Level 1 - Prices (not adjusted) quoted in active markets for identical assets and liabilities.
- Level 2 - Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices).
- Level 3 - Assumptions for the asset or liability that are not based on observable market data (unobservable inputs).

The level classification remained unchanged for the period ended September 30, 2014.

Estimated fair values

Estimated fair value for financial instruments was developed using a pricing model applied individually to each transaction, taking into account future payment flows based on contractual terms, discounted to present value at rates obtained through the market interest curve, based on information obtained from the BM&FBovespa and ANBIMA websites.

Therefore a security's fair value corresponds to its value at maturity (redemption value) brought to present value using a discount factor (related to the maturity date) obtained from the market interest curve in *Reais*.

Sensitivity analysis of financial assets and liabilities

The principal risks concerning the Company's operations relate to interbank (CDI) rate variations for promissory notes, debentures and marketable securities linked to the dollar exchange rate variation for loans and financing and marketable securities.

Notes to Quarterly Information

CDI Investments are recorded at fair value, in accordance with quotations disclosed by the corresponding financial institutions and the others refer mostly to banking deposit certificates and repurchase agreements, therefore the amount recorded for these securities shows no difference in relation to fair value.

Based on expectations stated in the FOCUS/Bacen report 09/26/14, a projection for the next 12 months was obtained, with an average of 11.41% for CDI and R\$ 2.42 for the exchange rate (R\$/US\$).

In order to verify the sensitivity of the index on marketable securities held by the Company at September 30, 2014, three different scenarios were defined, based on the projection and, from then on, the variations of 25% and 50% were calculated.

For each scenario gross financial expense / (income) was calculated, not including the impact of taxes and the flow of maturities of each contract scheduled for 2014.

| Transaction | Balance at September 30, 2014 | Risk | Scenario I (Probable) | Scenario II | Scenario III |
|---------------------------|--|-------------|----------------------------------|--------------------|---------------------|
| Marketable securities | 75,547 | Dollar | 956 | 18,887 | 37,773 |
| Rate subject to variation | | | 2.42 | 1.84 | 1.23 |
| Marketable securities | 499,773 | CDI | 57,024 | 42,768 | 28,512 |
| Rate subject to variation | | | 11.41% | 8.56% | 5.71% |

In order to verify the sensitivity of our debts index at September 30, 2014, three different scenarios were defined based on the projection, from which variations of 25% and 50% were calculated.

Gross financial expense was calculated for each scenario, not taking into consideration the impact of taxes and the flow of maturities of each contract scheduled for 2014. The reporting date used for financing was September 30, 2014, and the indices were projected for one year and their sensitivity determined for each scenario.

| Transaction | Balance at September 30, 2014 | Risk (a) | Scenario I | | |
|--------------------|--|-----------------|-------------------|--------------------|---------------------|
| | | | (Probable) | Scenario II | Scenario III |
| Debentures | 1,162,118 | CDI | 132,598 | 165,747 | 198,896 |
| | | | 11.41% | 14.26% | 17.12% |
| Working capital | 77,223 | CDI | 8,811 | 11,014 | 13,217 |
| | | | 11.41% | 14.26% | 17.12% |
| Working capital | 73,643 | Dollar | (931) | 18,411 | 36,822 |
| | | | 2.42 | 3.06 | 3.68 |

(a) Rate subject to variation

Notes to Quarterly Information

Fair value

| | Company | | | |
|-----------------------------|---------------------|-------------------|-------------------|-------------------|
| | 9/30/14 | | 12/31/13 | |
| | Book value | Fair value | Book value | Fair value |
| Assets | | | | |
| Marketable securities | 498,396 | 498,396 | 497,929 | 497,929 |
| Judicial deposits | 48,641 | 48,641 | 90,695 | 90,695 |
| Trade accounts receivable | 588,202 | 588,202 | 390,155 | 390,155 |
| Derivatives | - | - | 107 | 107 |
| Liabilities | | | | |
| Trade accounts payable | 79,226 | 79,226 | 45,804 | 45,804 |
| Debentures | 1,156,745 | 1,154,521 | 1,356,726 | 1,365,658 |
| Loans and financing: | | | | |
| Other bank loans | 90,567 | 90,164 | 8,431 | 8,431 |
| | | | | |
| | Consolidated | | | |
| | 9/30/14 | | 12/31/13 | |
| | Book value | Fair Value | Book value | Fair value |
| Assets | | | | |
| Marketable securities | 612,651 | 612,651 | 625,786 | 625,786 |
| Judicial deposits | 50,506 | 50,506 | 95,540 | 95,540 |
| Trade accounts receivable | 681,809 | 681,809 | 572,202 | 572,202 |
| Derivatives | - | - | 107 | 107 |
| Liabilities | | | | |
| Trade accounts payable | 87,530 | 87,530 | 65,479 | 65,479 |
| Debentures | 1,156,745 | 1,154,521 | 1,356,726 | 1,365,658 |
| Loans and financing: | | | | |
| Bank loan - Banco do Brasil | 77,223 | 76,820 | 23,884 | 23,954 |
| Bank loan - Credit Agricole | 73,643 | 73,643 | 70,623 | 70,623 |
| Other bank loans | 14,288 | 14,288 | 23,942 | 23,942 |
| | 165,154 | 164,751 | 118,449 | 118,519 |

25. Related parties

In the periods ended September 30, 2014 and 2013, the Company entered into transactions with related parties within its normal operating context, as shown below:

a) Transactions related to services rendered between Company and related parties

| | 9/30/14 | 12/31/13 |
|---|----------------|-----------------|
| Current assets - Customers | | |
| CientificaLab | 166 | 63 |
| CERPE | 91 | 78 |
| Previlab | 172 | 59 |
| | 429 | 200 |
| Current liabilities - Other accounts payable | | |
| DASA RE (i) | 196 | 73 |
| Sérgio Franco (ii) | - | 2,687 |
| | 196 | 2,760 |

Notes to Quarterly Information

| <u>Income for the period</u> | <u>9/30/14</u> | <u>9/30/13</u> |
|----------------------------------|----------------|----------------|
| Service revenue | | |
| CientificaLab | 2,144 | 1,700 |
| CERPE | 812 | 581 |
| Previlab | 627 | 714 |
| Lafê | 1,623 | - |
| | <u>5,206</u> | <u>2,995</u> |
| Cost of services provided | | |
| DASA RE (i) | 681 | 989 |
| CRMI Petrópolis (ii) | 72 | - |
| Sérgio Franco (ii) / (iii) | 18,304 | 17,620 |
| | <u>19,057</u> | <u>18,609</u> |

(i) Amounts corresponding to property rent.

(ii) Amounts corresponding to clinical analysis services.

(iii) Amounts corresponding to clinical analysis services provided until September 30, 2014.

Transactions with related parties, as shown above, are carried out at cost and eliminated in the consolidated quarterly information.

b) Advances for future capital contribution (AFAC)

| | <u>9/30/14</u> | <u>12/31/13</u> |
|---|----------------|-----------------|
| CientificaLab Produtos Laboratoriais e Sistemas Ltda. | 11,000 | 25,000 |

c) Management compensation

Total management compensation, including fixed compensation and bonuses, was R\$1,992 in the nine-month period ended September 30, 2014 (R\$2,006 in the nine-month period ended September 30, 2013), paid to the members of the Board of Directors (5 members in the period of nine months ended September 30, 2014 and 2013), and R\$7,689 in the nine-month period ended September 30, 2014 and R\$6,846 in the nine-month period ended September 30, 2013, paid to statutory officers (11 statutory officers in the nine-month period ended September 30, 2014 and 12 in the same period of 2013).

Changes occurred in share-based compensations are disclosed in Note 20 (a). There are no additional benefits to Company management.

d) Assignment of credits

Subsidiary Pro Echo (assignor) and the Company (assignee) entered into a credit assignment agreement on February 3, 2014, whereby the assignor assigns credits owned thereby to the assignee, amounting to R\$44,889, arising from intercompany loan agreements entered into with the following subsidiaries: (i) Laboratórios Médicos Dr. Sérgio Franco, amounting to R\$36,803, (ii) Check-up UP, amounting to R\$ 4,726, and (iii) CRMI, amounting to \$ 3,360. In consideration of the assignment, the Company pays R\$ 44,889 to subsidiary Pro Echo (assignor) at May 2, 2014.

e) Transactions between the Company and other related parties

Transactions with related parties are conducted at average regular market values, deadlines and rates prevailing on the respective dates and may be continuous.

Notes to Quarterly Information

The related parties that are included in the consolidated quarterly information are as follows:

Soldiers Field Serviços Administrativos Ltda.: Entity controlled by Marcelo Noll Barboza, member of the Company's Board of Directors and Statutory Audit Committee since July 24, 2014. Payments arise from obligations established in an agreement executed with the Company as a result of the expiration of the term of office, on April 27, 2012, for Chief Executive Officer (inauguration on October 1, 2008), and Chief Finance Officer and Investor Relations Officer (since February 12, 2012).

Link Consultoria em Medicina Diagnóstica Ltda.: an entity held by Alcione Moya Aprilante, shareholder of Previlab Análises Clínicas Ltda., which is a Company controlled by the DASA. It provides advisory services regionally in the management of health companies, and has market know-how, relationship with physicians practicing in the region where Previlab operates, as well as recognition by potential health professionals and customers.

Medparts Participações e Negócios Ltda.: entity held by Doctor Luciano Flávio Freitas de Almeida, member of Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda. - CERPE, which renders services to the Company, providing advisory services on business management of medical companies, with market know-how, relationship with local physicians, and recognition of potential professionals and customers in healthcare field.

Amar Administradora de Bens Próprios Ltda.: a company owned by M.D. Alcione Moya Aprilante and his wife, Melania Angelieri Cunha Aprilante. M.D. Alcione is a member of Previlab (a Company's subsidiary), which is the lessor of properties owned by AMAR, which belonged to Melania Angelieri Cunha Aprilante.

César Antonio Biazio Sanches: shareholder of Análises Clínicas Ltda., owner of the property leased by Previlab, which is an entity controlled by the Company, located at Rua Alferes Franco, nº 408 - Limeira, SP.

A e C Consultores Ltda.: an entity held by Cezar Antonio Biázio Sanches, shareholder of Previlab Análises Clínicas Ltda., which is a Company controlled by DASA. It provides business advisory and support services in the Previlab business area, as well as advisory, coaching, training and assessment of Previlab's employees and service providers.

Pesmed - Pesquisas e Serviços Médicos Ltda.: a Company controlled by Mr. Emerson Leandro Gasparetto, our radiology and graphical methods officer (elected March 26, 2012) and his wife, also a medical professional, Dr. Taisa Pallu Davaus Gasparetto, for consulting services in the form of medical research and surveys for former subsidiaries: (merged on July 1, 2014): CDPI – Clínica de Diagnósticos por Imagem Ltda, CRMI – Clínica de Ressonância e Multi Imagem Ltda. The amounts are calculated based on the number of reports actually prepared by Pesmed, with due regard for the amount corresponding to each type of report, as per the list prepared by Company, using the same system adopted for the other providers of services for the Company.

RMR Ressonância Magnética Ltda.: a Company with shareholders jointly holding 33.24% of its capital who are the brothers of Mr. Romeu Cortês Domingues, chairman of the board of directors of the Company (elected April 26, 2011), which provides medical services in the field of magnetic resonance imaging for former subsidiaries: (merged on July 1, 2014): CDPI – Clínica de Diagnósticos por Imagem Ltda; CRMI – Clínica de Ressonância e Multi Imagem Ltda; and Clínica de Ressonância e Multi-Imagem Caxias Ltda. Amounts are calculated based on revenue from magnetic resonance imaging services and numbers of exams produced by RMR, recognizing the corresponding charge for each type of report, as per the list prepared by the Company and using the same system adopted for the other providers of services for the Company.

Notes to Quarterly Information

Ultrascan Serviços de Imagem Ltda: Company owned by Eduardo Luiz Primo de Siqueira, who holds 7.5% of Clínica de Ressonância Multi-Imagem Petrópolis Ltda, which provides medical services in the imaging area for the controlled Company Clínica de Ressonância Multi-Imagem Petrópolis Ltda. The amounts are calculated based on the imaging service revenue and the number of reports prepared by Ultrascan, subject to the amount corresponding to each report type, according to the subsidiary's table, and they should further comply with the same system adopted for the other service providers of subsidiary.

DMG Laboratório Médico Ltda: a franchise of the controlled Company Laboratórios Médicos Dr. Sérgio Franco Ltda., whose managing partner is Neusa de Godoy Bueno Joaquim, mother-in-law of the regional chief financial officer of the former subsidiaries: (merged on July 1, 2014) Company Laboratórios Médicos Dr. Sérgio Franco Ltda., Carlos Fabio Ferreira Xavier. The franchise commission is calculated based on DMG's service revenue, subject to the same system adopted for the other franchisees.

Lâmina Laboratório de Patologia Prevenção de Câncer Ltda: an entity whose partner is Adília Jane de Alcântara Segura, non-statutory medical officer of the Company, for clinical pathology services. The amounts are calculated based on the number of examinations effectively made by Lâmina, subject to the amount corresponding to each examination type, according to the Company table and pursuant to the same system adopted for the other services providers.

ECRD - Serviços Médicos de Radiologia Ltda: The Company's partner is Mr. Roberto Cortes Domingues, brother of Mr. Romeu Cortês Domingues, chairman of the Board of Directors (appointed on April 26, 2011), which provides medical services referring to MRI and radiology for former subsidiaries: (merged on July 1, 2014) CDPI – Clínica de Diagnósticos por Imagem Ltda., CRMI - Clínica de Ressonância e Multi Imagem Ltda. and Clínica de Ressonância e Multi-Imagem Caxias Ltda. and subsidiary Clínica de Ressonância e Multi-Imagem Petrópolis Ltda.

Amil Group (Amil International; Amico and Dix): Mr. Edson Godoy Bueno, together with Dulce Pugliese de Godoy Bueno, is the Company's controlling shareholder and also Chief Executive Officer of the Amil Group, to which the Company and its subsidiaries provide medical diagnosis services. The Company and its subsidiaries also engaged the Amil Group to provide employees' health plan management services.

Amil Impar / Amil Par: Mr. Edson Godoy Bueno and Dulce Pugliese de Godoy Bueno, controlling shareholders of the Company and also of Amil Impar and Amil Par, holding equity interest in hospitals in which the Company and its subsidiaries provide medical diagnosis services.

Patrys Investimentos Imobiliários Ltda. (former EGB 01 Empreendimentos e Participações Ltda): Mr. Edson Godoy Bueno and Dulce Pugliese de Godoy Bueno, controlling shareholders of the Company and also of EGB, which has properties under lease with the Company and its subsidiaries.

Notes to Quarterly Information

The amount of such transactions with related parties is as follows:

| | Assets/ (Liabilities) | | | Assets/ (Liabilities) | | |
|--|-----------------------|-------|------------|-----------------------|-------|------------|
| | 9/30/14 | | | 12/31/13 | | |
| | Services | Rents | Healthcare | Services | Rents | Healthcare |
| - Soldiers Field Serviços Administrativos Ltda. | 266 | - | - | 619 | - | - |
| - Soldiers Field Serviços Administrativos Ltda. | (420) | - | - | (1,044) | - | - |
| - Link Consult. em Medicina Diag. Ltda. | (15) | - | - | (15) | - | - |
| - Amar Admin. de Bens Próprios Ltda. | - | (30) | - | - | - | - |
| - César Antonio Biazio Sanches | - | (6) | - | - | (6) | - |
| - A e C Consultores Ltda. | (35) | - | - | (5) | - | - |
| - DMG Laboratório Médico Ltda. | (22) | - | - | (18) | - | - |
| - Grupo AMIL (AMIL Internacional; Amico e Dix) (a) | 78,748 | - | (1,268) | 56,281 | - | (27) |
| - AMIL Impar / AMIL Par (a) | 25,574 | - | - | 17,830 | - | - |
| - Patrys Investimentos Imobiliários Ltda. | - | (434) | - | - | (184) | - |

(a) the reported amount of asset balances for services rendered by the Company and its subsidiaries is net of provision for disallowance, as well as financial discounts granted. The amount of R\$78,748 includes R\$4,472 related to a debt acknowledgment and installment payment agreement performed on June 9, 2014.

| | Income / (Expenses) | | | Income / (Expenses) | | |
|---|---------------------|---------|------------|---------------------|---------|------------|
| | 9/30/14 | | | 9/30/13 | | |
| | Services | Rents | Healthcare | Services | Rents | Healthcare |
| - Soldiers Field Serviços Administrativos Ltda. | (236) | - | - | (255) | - | - |
| - Link Consult. em Medicina Diag. Ltda. | (142) | - | - | (142) | - | - |
| - Medparts Partícip. e Negócios Ltda. | (200) | - | - | (187) | - | - |
| - Amar Admin. de Bens Próprios Ltda. | - | (235) | - | - | (141) | - |
| - César Antonio Biazio Sanches | - | (77) | - | - | (62) | - |
| - A e C Consultores Ltda. | (315) | - | - | (299) | - | - |
| - Pesmed – Pesquisas e Serv. Médicos Ltda. | (198) | - | - | (281) | - | - |
| - RMR Ressonância Magnética Ltda. | (1,290) | - | - | (2,718) | - | - |
| - Ultrascan Serviços de imagem Ltda. | (148) | - | - | (126) | - | - |
| - DMG Laboratório Médico Ltda. | (846) | - | - | (739) | - | - |
| - Lâmina Lab.de Patologia Prev.de Câncer Ltda. | - | - | - | (169) | - | - |
| - ECRD – Serviços Médicos de Radiologia Ltda.) | (1,390) | - | - | (510) | - | - |
| - Grupo AMIL (AMIL Internacional; Amico e Dix) | 318,542 | - | (27,099) | 299,445 | - | (12,790) |
| - AMIL Impar / AMIL Par | 85,603 | - | - | 73,207 | - | - |
| - Patrys Investimentos Imobiliários Ltda. | - | (4,351) | - | - | (3,837) | - |

Notes to Quarterly Information**26. Financial and operating lease**Local currency leases

The Company leases goods recorded in property and equipment, subject to agreements as follows: with no renewal option, and contingent payment, with no covenants referring to dividends and interest on equity or additional debt. These contracts total an amount payable of R\$5,430 at the parent Company until 2015 for the consolidated, given that the sum of R\$4,284 of this amount is recorded in current liabilities and R\$1,146 in noncurrent liabilities.

The average term of the contracts is 36 months and these are remunerated at interest rate varying from CDI + 1.53% p.a. to CDI + 2.00% p.a.

Future minimum payments under loans and financing (see Note 15) are segregated as follows:

| | 9/30/14 | | | | | |
|-------------------|---|------------|-------------------------|--------------------------------|------------|-------------------------|
| | Company | | | Consolidated | | |
| | Present value of minimum Lease Payments | Interest | Future minimum payments | Future Minimum Payments Future | Interest | Future Minimum Payments |
| Up to one year | 4,284 | 93 | 4,377 | 4,284 | 93 | 4,377 |
| One to five years | 1,146 | 25 | 1,171 | 1,146 | 25 | 1,171 |
| | 5,430 | 118 | 5,548 | 5,430 | 118 | 5,548 |

| | 12/31/13 | | | | | |
|-------------------|---|----------|-------------------------|--------------------------------|------------|-------------------------|
| | Company | | | Consolidated | | |
| | Present value of minimum lease payments | Interest | Future minimum payments | Future Minimum Payments Future | Interest | Future Minimum Payments |
| Up to one year | 2 | - | 2 | 8,028 | 171 | 8,199 |
| One to five years | - | - | - | 3,073 | 65 | 3,138 |
| | 2 | - | 2 | 11,101 | 236 | 11,337 |

Domestic finance lease agreements are included in property and equipment under devices and equipment, amounting to R\$13,826 (R\$15,236 at December 31, 2013) in Consolidated.

Foreign currency financial leases

The Company leases equipment used to provide services, according to lease agreements with purchase option, with no renewal option, and contingent payment, with no covenants referring to dividends and interest on equity or additional debt. The payment term is 84 months. For the first installment of a shortage of 6 months for the settlement was established, and the remaining payments on a quarterly and semiannually. The quarterly and semi-annual installments in U.S. dollars are translated into reais at the market exchange rate effective on the payment date, plus interest from 7.20% per annum to 8.35% per annum, the balance payable totaling R\$3,485 by 2016, R\$3,272 thereof being recorded under current liabilities and R\$213 under noncurrent liabilities.

Notes to Quarterly Information

Future minimum payments are segregated as follows:

| | 9/30/14 | | | | | |
|-------------------|---|------------|-------------------------|---|------------|-------------------------|
| | Company | | | Consolidated | | |
| | Present value of minimum lease payments | Interest | Future minimum payments | Present value of minimum lease payments | Interest | Minimum Future payments |
| Up to one year | 2,585 | 132 | 2,717 | 3,272 | 168 | 3,440 |
| One to five years | 213 | 11 | 224 | 213 | 11 | 224 |
| | 2,798 | 143 | 2,941 | 3,485 | 179 | 3,664 |

| | 12/31/13 | | | | | |
|-------------------|---|------------|-------------------------|---|------------|-------------------------|
| | Company | | | Consolidated | | |
| | Present value of minimum Lease payments | Interest | Future minimum payments | Present value of minimum lease payments | Interest | Minimum future payments |
| Up to one year | 6,626 | 403 | 7,029 | 7,893 | 480 | 8,373 |
| One to five years | 1,803 | 109 | 1,912 | 2,140 | 130 | 2,270 |
| | 8,429 | 512 | 8,941 | 10,033 | 610 | 10,643 |

The international finance lease agreements are included in property and equipment as machinery and equipment, totaling R\$3,968 (R\$8,002 at December 31, 2013) - Company and R\$4,330 (R\$8,687 at December 31, 2013) - consolidated.

Operating lease

Future minimum property rent payable on operating leases not subject to cancellation in consolidated are the following:

| | 9/30/14 | | | 12/31/13 | | |
|--|-------------------------|----------------------------|----------------|-------------------------|----------------------------|----------------|
| | Fixed-income agreements | Variable income agreements | Total | Fixed-income agreements | Variable income agreements | Total |
| Within one year | 133,134 | 2,044 | 135,178 | 100,046 | 4,123 | 104,169 |
| More than one year, but less than five years | 323,182 | 4,962 | 328,144 | 177,826 | 7,329 | 185,155 |
| More than five years | 111,954 | 1,299 | 113,253 | 98,812 | 270 | 99,082 |
| | 568,270 | 8,305 | 576,575 | 376,684 | 11,722 | 388,406 |

27. Net revenue

Reconciliation between gross revenues for tax purposes and net revenues and discounts stated in the income statements is as follows:

| | Company | | Consolidated | |
|--|------------------|------------------|------------------|------------------|
| | 9/30/14 | 9/30/13 | 9/30/14 | 9/30/13 |
| Gross revenue | 1,782,945 | 1,471,693 | 2,277,610 | 2,055,677 |
| Deductions: | | | | |
| Taxes | (107,160) | (83,522) | (135,944) | (115,102) |
| Provision for and losses due to disallowance and default | (45,418) | (52,198) | (57,974) | (76,111) |
| Discounts | (4,846) | (5,099) | (6,299) | (5,373) |
| | 1,625,521 | 1,330,874 | 2,077,393 | 1,859,091 |

Notes to Quarterly Information**28. Financial income**

| | Company | | Consolidated | |
|--|------------------|----------------|---------------------|----------------|
| | 9/30/14 | 9/30/13 | 9/30/14 | 9/30/13 |
| Financial expenses | | | | |
| Interest | (117,995) | (101,029) | (121,715) | (117,203) |
| Monetary and exchange variation losses | (1,475) | (5,790) | (1,388) | (10,662) |
| Discounts granted (a) | (2,322) | (2,992) | (6,083) | (3,183) |
| Other | (7,853) | (6,834) | (12,045) | (10,014) |
| | (129,645) | (116,645) | (141,231) | (141,062) |
| Financial income | | | | |
| Interest | 49,876 | 16,226 | 63,438 | 21,959 |
| Monetary and exchange variation losses | 1,186 | 5,982 | 1,557 | 7,654 |
| Other | 494 | 43,875 | 1,478 | 45,008 |
| | 51,556 | 66,083 | 66,473 | 74,621 |
| | (78,089) | (50,562) | (74,758) | (66,441) |

(a) Discounts granted to customers in the amount of R\$2,276 - Company and R\$5,980 - Consolidated.

Dickson Esteves Tangerino
CEO

Márcio Ramos Fernandes
Financial Director and Vice-President

Carlos Elder Maciel de Aquino
Chief Accounting Officer and Infrastructure

Paulo Bokel Catta-Preta
Investor Relations Director and CFO

Daniel Vendramini da Silva
TC-CRC 1SP125812/O-1

Other Information Considered Relevant by the Company**Shareholding structure**

Controlling shareholders, managing officers and outstanding shares

| Shareholders | Position at September 30, 2014 | | | |
|---------------------------|--------------------------------|----------------|------------------------|----------------|
| | Common shares (unit) | % | Total shares (unit) | % |
| Controllers | 224,308,396 | 71.94% | 224,308,396 | 71.94% |
| Board of directors | 7,472,934 | 2.40% | 7,472,934 | 2.40% |
| Staff of officers | 83,538 | 0.03% | 83,538 | 0.03% |
| Statutory Audit Committee | 1 | 0.00% | 1 | 0.00% |
| Treasury stock | 1,052,459 | 0.34% | 1,052,459 | 0.34% |
| Outstanding shares | 78,885,687 | 25.30% | 78,885,687 | 25.30% |
| Total of shares | 311,803,015 | 100.00% | 311,803,015 | 100.00% |

| Shareholders | Position at September 30, 2013 | | | |
|---------------------------|--------------------------------|----------------|------------------------|----------------|
| | Common shares (unit) | % | Total shares (unit) | % |
| Board of directors | 7,470,953 | 2.40% | 7,470,953 | 2.40% |
| Staff of officers | 69,866 | 0.02% | 69,866 | 0.02% |
| Statutory Audit Committee | 1 | 0.00% | 1 | 0.00% |
| Treasury stock | 1,159,035 | 0.37% | 1,159,035 | 0.37% |
| Outstanding shares | 303,103,160 | 97.21% | 303,103,160 | 97.21% |
| Total of shares | 311,803,015 | 100.00% | 311,803,015 | 100.00% |

At September 30, 2014 and 2013, the Company did not have a Supervisory Board.

Arbitration clause

The Company is bound to arbitration by the Market Arbitration Chamber, pursuant to the arbitration clause provided for in its articles of incorporation.

Independent auditor's review report on quarterly financial information

A free translation from Portuguese into English of Independent Auditor's Review Report on individual quarterly financial information prepared in accordance with Accounting Pronouncement CPC 21 (R1) - Interim Financial Reporting and consolidated interim quarterly financial information prepared in accordance with CPC 21 (R1) and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB)

Independent auditor's review report on quarterly financial information

The Shareholders, Board of Directors and Officers

Diagnósticos da América S.A.

São Paulo - SP

Introduction

We have reviewed the accompanying individual and consolidated interim financial information of Diagnósticos da America S.A. and subsidiaries (the "Company"), contained in the Quarterly Information Form (ITR) for the quarter ended September 30, 2014, which comprises the balance sheet as at September 30, 2014 and the related statements of income, and statements of comprehensive income for the three and nine-month periods then ended, and the statements of changes in equity and statements of cash flow for the nine-month period then ended, including accompanying notes.

Management is responsible for the preparation of the individual interim financial information in accordance with Accounting Pronouncement CPC 21 (R1) - Interim Financial Reporting, and consolidated interim financial information in accordance with CPC 21 (R1) and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as for the fair presentation of this information in conformity with the standards issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Financial Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Review Engagements (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independent auditor's review report on quarterly financial information

Conclusion on the individual interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the individual interim financial information included in the quarterly financial information referred to above is not prepared, in all material respects, in accordance with CPC 21 (R1) applicable to the preparation of Quarterly Information (ITR), and presented consistently with the standards issued by the Brazilian Securities and Exchange Commission (CVM).

Conclusion on the consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the consolidated interim financial information included in the quarterly financial information referred to above is not prepared, in all material respects, in accordance with CPC 21 (R1) and IAS 34 applicable to the preparation of Quarterly Information (ITR), and presented consistently with the standards issued by the Brazilian Securities and Exchange Commission (CVM).

Other matters

Statements of value added

We also reviewed the individual and consolidated statements of value added (SVA), for the nine-month period ended September 30, 2014, prepared under the responsibility of Company management, whose presentation in the interim financial information is required by the standards issued by the Brazilian Securities and Exchange Commission (CVM), applicable to preparation of Quarterly Information (ITR) and considered supplementary information under IFRS, which do not require SVA presentation. These statements were submitted to the same review procedures previously described and, based on our review, nothing has come to our attention that would make us believe that they were not prepared, in all material respects, consistent with the overall individual and consolidated interim financial information.

São Paulo, November 10, 2014.

ERNST & YOUNG
Auditores Independentes S.S.
CRC-2SP015199/O-6

Antonio Carlos Fioravante
Accountant CRC-1SP184973/O-0

Rita de C. S. de Freitas
Accountant CRC-1SP214160/O-5

Opinions and Statements/Statement of Officers on the Quarterly Information

Observing the provision of article 25 of Ruling No. 480/09 of December 7, 2009, the Board represents that it has reviewed, discussed and agreed with the Quarterly information (Company and Consolidated) for period ended September 30, 2014.

Barueri, November 10, 2014.

CEO - Dickson Esteves Tangerino

Financial Director and Vice-President – Márcio Ramos Fernandes

Investor Relations Officer and Financial and CFO - Paulo Bokel Catta-Preta

Chief Accounting Officer and Infrastructure - Carlos Elder Maciel de Aquino

Opinions and Declarations/Statement of Officers on the Independent Auditors Report

In compliance with the provisions of article 25, Instruction # 480/09, of December 7, 2009, the Staff of Officers represents that it has reviewed, discussed and agreed with the opinion expressed in the Independent Auditors' Review Report, dated August 11, 2014, related to the quarterly information (Company and Consolidated) for the period ended on September 30, 2014.

Barueri, November 10, 2014.

CEO - Dickson Esteves Tangerino

Financial Director and Vice-President - Márcio Ramos Fernandes

Investor Relations Officer and Financial and CFO - Paulo Bokel Catta-Preta

Chief Accounting Officer and Infrastructure - Carlos Elder Maciel de Aquino